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Desde Quito
hasta el fin de la tierra
yo caminé tu piel,
en ella me interné,
me la aprendí al dedillo.
En ella caí en éxtasis,
de nuevo volvi en mí,
me di las vueltas,
apaciguado a veces;
a veces desbocado,
lúcido hasta más no poder,
sonámbulo, enviciado,
ensimismado, entimismado,
con el tacto borracho,
viviendo en la candela.
Un día 
cuando salía el sol
por donde nunca,
con estos ojos
que han de hacerse tierra
yo vi como en tu piel
pastaban las palabras. 
-Euler Granda
“Entre la gente y el humo de 
los carros” de la colección
Relincha el sol, 1997
From Quito
to the end of the earth
I walked your skin,
I wrapped myself in it,
I learned it down to the last finger.
I fell into the ecstasy of it
came to myself again,
made the rounds,
sometimes appeased;
sometimes out of control,
lucid to the max,
a sleepwalker, an addict,
stuck inside myself, stuck with you,
with a drunken touch,
living in the fire.
One day
as the sun rose
somewhere new,
with these eyes
that will surely turn to dust
I saw that on your skin,
words were grazing.
-Euler Granda, Ecuadorian poet
(Translation is mine. -CMS)
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We know very little, and yet it is astonishing that we know so much, and still more 
astonishing that so little knowledge can give us so much power.
-Bertrand Russell 
in his book, ABC of Relativity 
in the right light, study becomes insight
-Rage Against the Machine
"Take the Power Back" 
from their self-titled album
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DEDICATION
For my mother.  
Because it was she who repeated, 
“I really think you’d like biology,” 
when I was convinced that I should go into international relations.
  Perhaps we were both right. 
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ABSTRACT
As humans, we inhabit an environment shared with many microorganisms, some 
of which are harmless or beneficial, and others which represent a threat to our 
health.  A complex network of organs, cells and their protein products form our 
bodies’ immune system, tasked with detecting these potentially harmful agents 
and eliminating them.  This same system also serves to detect changes in the 
healthy balance of normal functions in the body, and for repairing tissue damage 
caused by injury.  Immune recognition of nucleic acids, DNA and RNA, is one 
way that the body detects invading pathogens and initiates tissue repair.  A 
number of specialized receptor proteins have evolved to distinguish nucleic acids 
that represent “threats” from those involved in normal physiology.  These proteins 
include members of the Toll-like receptor family and diverse types of cytosolic 
proteins, all of which reside within the confines of the cell.  Few proteins on the 
cell surface have been clearly characterized to interact with nucleic acids in the 
extracellular environment.  In this dissertation, I present collaborative work that 
identifies the receptor for advanced glycation end products (RAGE) as a cell 
surface receptor for nucleic acids  and positions it as an important modulator of 
immune responses.  Molecular dimers of RAGE interact with the sugar-
phosphate backbones of nucleic acid ligands, allowing this receptor to recognize 
a variety of DNA and RNA molecules  regardless of their nucleotide sequence. 
Expression of RAGE on cells promotes uptake of DNA and enhances 
ix
subsequent responses that are dependent on the nucleic acid sensor Toll-like 
receptor 9.  When mice deficient in RAGE are exposed to DNA in the lung, the 
predominant site of RAGE expression, they do not mount a typical early 
inflammatory response, suggesting that RAGE is important in generating immune 
responses to DNA in mammalian organisms.  Further evidence suggests that 
RAGE interacts preferentially with multimolecular complexes that contain nucleic 
acids, and that these complexes may induce clustering of receptor dimers into 
larger multimeric structures.  Taken together, the data reported here identify 
RAGE as an important cell surface receptor protein for nucleic acids, which is 
capable of modulating the intensity of immune responses to DNA and RNA. 
Understanding of and intervention in this recognition pathway hold therapeutic 
promise for diseases characterized by excessive responses to self nucleic acids, 
such as systemic lupus erythematosus, and for the pathology caused by chronic 
inflammatory responses to self and foreign nucleic acids.   
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CHAPTER I: Introduction
1
 The mammalian immune system is a complex network of specialized 
organs and cells  that perform surveillance of the body’s physical integrity and 
enact mechanisms to eliminate agents that pose a threat to normal physiological 
functions.  The ability to effectively distinguish “self” from “foreign” and control 
interactions between the two is what allows us, as  humans, to persist for long 
periods in an environment full of microbes and parasites that wish to benefit from 
the resources afforded by our bodies.  At the same time, we derive great benefit 
from a large number of commensal microorganisms whose presence, while not 
strictly “self,” does not pose a direct threat to our health and integrity.  Given the 
large number of microorganisms and parasites in our environment, as well as the 
variety of threats and benefits  these organisms pose, the immune system 
requires sophisticated mechanisms for distinguishing and controlling the 
interactions of these “foreign” agents with our “self” environment.  In recent 
years, it has become clear that the same immune system that recognizes foreign 
agents  also plays a role in detecting self-derived signals  that indicate 
homeostatic perturbations.  Thus, the ability to discern potential danger from 
normalcy is both complex and essential for survival.  Internal errors  in the 
functioning of the immune system can have serious consequences: exaggerated 
responses to harmless agents, as  seen in allergy and hypersensitivities, the 
mistaken recognition of self as foreign, leading to self-directed attacks  known as 
autoimmunity, and collateral damage to self tissues, termed pathology. 
Understanding the ways the immune system functions at the molecular level not 
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only provides insight into the fascinating way that our bodies interact with their 
environment, but also helps us to devise strategies  to correct immune “errors” 
and create more effective therapies for diseases.
Molecular patterns initiate innate immune responses
As might be expected for a system that must discriminate between a large variety 
of potential activators, responses of the immune system occur in several 
interconnected phases.  In the broadest of terms, these phases are grouped into 
those of the early, “innate” immune response and a subsequent “adaptive” 
response.  Both early and late responses are mediated by specialized cells and 
the effector molecules they produce, but the specificity of these cells and 
associated proteins differ in important ways.  The innate immune response is 
characterized predominantly by the recognition of conserved “molecular patterns” 
that are common among certain classes  of pathogens (so-called pathogen-
associated molecular patterns, PAMPs), microbes in general (microbial-
associated molecular patterns, MAMPs) or substances that present themselves 
during conditions  of injury or infection (danger-associated molecular patterns, 
DAMPs).  The chemical nature of these molecular patterns allows them to 
interact with germline-encoded receptor proteins expressed on the surface of 
cells or within them, predominantly effector cells  of the immune system. 
Engagement of such innate immune receptor proteins initiates signaling 
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cascades that result in gene transcription and the production of effector 
molecules, as well as  downstream molecular signals.  Many of these signals then 
converge on additional cell types and receptors with more restricted specificities, 
which compose the “adaptive” phase of the immune response. While the innate 
phase rapidly detects signs of infection or damage and begins to control the 
sources, the adaptive phase completes this  process and generates long-lasting 
immunological memory.   
 Molecular patterns  take a wide variety of chemical forms, including 
proteins and lipids of bacterial cell walls and membranes, fungal structural 
proteins, certain carbohydrate conformations, and electrostatically-charged 
molecules.  While many of these “patterns” are highly conserved among certain 
types of microorganisms, the most highly conserved molecules of all, that is, the 
basic genetic materials  of life, are also a means the immune system uses to 
sense danger.  Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) 
molecules are potent activators of immune responses  and tissue repair 
processes.       
Immunostimulatory nucleic acids as molecular patterns
The notion that nucleic acids  could stimulate an immune response emerged in 
the 1960’s, with the realization that viral genetic material induced the production 
of interferons, molecules that promote changes in cells  that “interfere” with viral 
proliferation.1 The essential conundrum of distinguishing one’s own nucleic acids 
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from those of an invading virus was recognized during this early work and is 
articulated by Rotem and colleagues in a 1963 paper in Nature:
“...if viral  nucleic  acid is the stimulus to make interferon this poses an awkward 
problem, since both DNA and RNA viruses are able to induce its production.  This 
suggested a hypothesis -- that the essential stimulus to make interferon might be 
nucleic acid that was ‘foreign‘ to the cell.”1  
     
The characteristics that defined RNA and DNA molecules as  “foreign” emerged 
over the next several decades and continue to be refined by recent work. 
Interferon stimulation was first tied to the presence of long stretches of double-
stranded RNA2, which commonly occur during viral replication but are not native 
to mammalian cells, where RNA does not persist in a double-stranded state.  By 
the 1970’s both natural and synthetic double-stranded RNAs had been identified 
as stimulators  of interferon and the therapeutic potential of synthetic 
polyriboinosinic:polyribocytidilic acid (poly I:C) against viral infections had been 
noted3.  Additional immunostimulatory characteristics  of RNA unrelated to 
double-strandedness emerged more than 30 years after these initial 
observations, and include the presence of a 3’ triphosphate, certain sequence 
motifs, and particular secondary structures4.  Recognition of DNA as an inducer 
of immune responses gained force in the early 1990s, with work that defined 
DNA-rich mycobacterial extracts as potent instigators of inflammation5.  These 
and similar microbial DNA extracts, as well as synthetic oligonucleotides  based 
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on microbial genetic sequences, were shown to have antitumor activity6 and 
adjuvant effects, and activate specific subsets of immune cells7,8. Many of these 
studies pointed to specific sequence motifs  that appeared to be required for 
stimulating immune effects, the most elemental of which was an unmethylated 
cytosine-phosphate-guanine (CpG) dinucleotide contained within palindromic 
sequences5,8.  These studies  grew into a subfield of research around the 
therapeutic effects of “antisense” DNA molecules, and the subsequent creation of 
many synthetic oligonucleotides that have proven useful for activating nucleic 
acid sensing pathways in experimental and therapeutic contexts.  
Toll-like receptors
Discovery
While the RNA and DNA immune activators and their biological effects  became 
more and more defined, an essential link was missing: what molecule or 
molecules sensed these nucleic acids and instigated cytokine production?  In this 
context, the description by Hemmi and colleagues of a Toll-like receptor protein 
that mediates responses to bacterial DNA9 began a period of revelation in the 
understanding of nucleic acid sensing.  This DNA-binding Toll-like receptor, 
TLR9, recognizes double-stranded (ds) and single-stranded (ss) DNA by means 
of interaction with unmethylated cytosine-phosphate-guanine (CpG) dinucleotide 
motifs and surrounding nucleotide bases. Optimal CpG motif sequences 
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generally consist of a cytosine followed directly in the 3’ direction by a guanine 
and surrounded by particular combinations of purine and pyrimidine bases.  Such 
motifs are common in bacterial and viral genomes, but are infrequent and 
methylated in the human genome.  A wide range of synthetic oligonucleotides 
incorporating CpG motifs and stabilizing structural elements  have been 
developed that are able to selectively induce and block TLR9 signaling10-13.  
 At the time that TLR9 was described, the Toll-like receptor field was 
blossoming.  The description in 1997 of the first human homolog of the 
Drosophila receptor Toll, TLR4, and the realization that it mediated mammalian 
responses to the potent bacterial PAMP, lipopolysaccharide (LPS)14-16, 
revolutionized the study of innate immunity.  Seemingly in a heartbeat, genes for 
five structurally-related TLRs were defined and named TLR1 through TLR517, 
and TLR6 was described soon after18.  All of these new TLRs were assumed to 
play roles in immune pattern recognition19, but identification of their specific 
ligands lagged behind their molecular cloning.  On the heels  of TLR4, TLR2 was 
found to recognize bacterial membrane lipids distinct from LPS20-24 and TLRs 1 
and 6 were subsequently shown to heterodimerize with TLR2 in response to 
subsets of these PAMPs25,26.  A flurry of research surrounding TLRs 2 and 4 had 
firmly established a key role for this receptor family in sensing of bacterial 
components.  The description of TLR9 as a receptor for bacterial DNA thus not 
only contributed another member to the panel of bacteria-detecting receptors, but 
also indicated that the first clear DNA-sensing receptor protein was a TLR.  Soon 
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thereafter, dsRNA was defined as a ligand for TLR327, thus consolidating a role 
for TLRs in nucleic acid sensing and serving as  a link between 
immunostimulatory nucleic acids and cytokine production.   
Protein structure
Toll-like receptors are a family of structurally-related transmembrane proteins, 
possessing extracellular (or simply, “ecto-”) domains that contain a series  of 
repeating leucine-rich sequences (“leucine-rich repeats” or LRRs), a single 
hydrophobic transmembrane region, and a cytosolic domain with homology to 
members of the interleukin-1 receptor family, termed the Toll IL-1 receptor (TIR) 
domain.  Variations in the number and length of LRRs have led to classification of 
the TLRs into structural subfamilies28, while homology of the TIR domains allows 
for homotypic association with TIR domains of downstream adaptor molecules 
that facilitate signal transduction29.  A total of 13 TLRs have been defined in 
humans (TLR1-10) and mice (TLR1-9, 11-13), while other vertebrate and 
invertebrate animals possess diverse and less-studied repertoires30-32.  
Endosomal TLRs
TLR9 was cloned and described together with two other novel Toll-like receptors, 
dubbed TLR7 and 833,34 and these three receptors were shown to share a longer 
ectodomain structure, distinguishing them as a structurally-distinct subfamily from 
the six previously described TLRs.  TLRs 7-9 were subsequently recognized to 
8
differ in another key way: they were expressed on intracellular membranes, 
rather than at the cell surface.  TLRs 1, 2, 4, 5, 6 and 10 are all expressed on the 
plasma membrane, while TLRs 7, 8, 9, along with TLR3*1, are expressed in the 
endoplasmic reticulum of resting cells.  Upon appearance of ligands, these 
intracellular TLRs relocate to endosomal compartments, and are thus sometimes 
referred to collectively as endosomal TLRs.  Interestingly, as ligands for the 
remaining endosomal TLRs emerged, it became clear that these receptors had 
something else in common: they all recognize nucleic acids.  TLR3 was found to 
sense viral dsRNA27 and this recognition extended to synthetic dsRNA molecules 
like poly I:C.  The first defined ligands for TLRs 7 and 8 were synthetic 
ribonucleoside analog drugs35, but the ability of these receptors to recognize 
specific types of viral or synthetic ssRNA eventually became clear36.     
Endosomal localization in TLR function
The fact that nucleic acid sensing TLRs are all grouped into the same 
intracellular membrane-bound compartments would seem to suggest that this 
localization is  vital for effective sensing of foreign nucleic acids.  As  the 
environment in which all TLR:nucleic acid functional interactions appear to occur 
is  within endosomes, it helps  to consider some generalities of endosome 
biology37 when contemplating nucleic acid sensing in this  environment.  The main 
function of the endosomal network is  to transport materials -- macromolecules, 
9
1 TLRs 11257 and 13258 are also expressed on intracellular membranes
whole or fragmented microorganisms, crystalline materials, etc.-- from the 
extracellular environment into the cell.  Formation of an endosome generally 
requires a signal from proteins on the cell surface that recognize potential 
endosome “cargo,” processes known as receptor-mediated endocytosis  and 
phagocytosis.  Passive uptake of some receptor proteins and soluble materials in 
extracellular fluid also occur constantly as  a result of pinocytosis.  Endocytosis 
initiates when a region of plasma membrane buds inward, enclosing membrane-
bound proteins and cargo components in a vesicle, which soon fuses with a 
larger endosome near the cell surface.  As a result, the endosome lumen is, 
essentially, a continuation of the “extracellular” environment, though no longer in 
direct contact with it.  Hence, the lumen-exposed “ectodomains” of TLRs 3, 7-9 
are functionally similar to the “extracellular” domains of TLRs 1, 2, 4-6. 
Endosomes that fuse directly with vesicles  from the plasma membrane are called 
“early” endosomes and are characterized by an acidic pH of around 6.  This pH is 
maintained by hydrogen-transporting ATPases and often facilitates release of 
cargo from receptor proteins. Some of these proteins will be transferred to 
vesicles that fuse with distinct, “recycling” endosomes for return to the cell 
surface.  Other receptors, and nearly all endosome cargo, remain in the acidified 
compartment, which through a number of fusion events, matures  into a “late” 
endosome.  Endosomal maturation is  a dynamic process characterized by 
vesicle movement along the cytoskeleton and iterative changes in membrane 
protein composition.  Certain proteins, most notably those of the Rab GTPase 
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family, are thought to form “labels” that promote recognition of different types of 
endosomes by other vesicular bodies38.  These endosomal “markers” can be 
exploited to identify specific endosomal compartments under experimental 
conditions.  Fusion of late endosomes with vesicles containing acid-dependent 
proteases and lipases forms a degradative compartment known as the lysosome 
or endolysosome, in which microbes and macromolecules are broken down.
 The acidification of the endosomal compartment has been shown to be 
essential for activation of TLR9 by DNA ligands39,40, and similar requirements 
appear to exist for activation of TLR7 and 8 by their ligands41.  Several 
hypotheses have been put forth to explain why nucleic acids must meet TLR9 in 
an acidified endosome for activation (refer to 42 and 43):
1.  Low pH and activation of acid-dependent degradative enzymes modify ligands 
in a manner necessary for their recognition by the receptor.  While this may be 
true for DNA molecules themselves, it would seem to be of greater importance 
for extracting nucleic acids from viral particles, bacterial cells or parasites. 
Similarly, these chemical changes might help to physically separate DNA from 
delivery vectors such as malarial hemozoin44, artificial transfection agents, or 
co-receptor proteins.  
2. Acid-dependent proteases directly modify TLR9 to enable receptor 
engagement by ligands. This idea, initially put forth by Ploegh and 
colleagues45, has  been a controversial one.  It now appears that, although 
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TLR9 cleavage is  not required for ligand binding, it is  important for downstream 
signaling of endogenous TLR946. Some indirect evidence indicates  that a 
similar cleavage mechanism could also affect TLR7 activation47.  
3. The restricted dimensions and specific chemistry of the endosome serve to 
concentrate TLR 9 ligands, thus surpassing an activation threshold.    
4. Its  ability to enter an endosomal compartment serves as an indicator that a 
given nucleic acid molecule requires the attention of the immune system. 
Since a healthy cell’s own genomic DNA is confined to the nucleus and its 
RNA functions in either the nucleus or the cytosol, sequestering nucleic acid- 
sensing TLRs in endosomes restricts their access solely to nucleic acids 
originating from extracellular sources.  
Support for this final hypothesis was convincingly developed in work by Barton 
and colleagues42.  In an elegant series of experiments, they showed that 
swapping the transmembrane and intracellular domains of TLR9 with TLR4 
directed the chimeric TLR9 protein to the plasma membrane and enabled it to 
recognize self-derived DNA in the extracellular milieu.  This strongly supported 
the idea that sequestration of TLRs in endosomal compartments  was the key 
determinant in preventing their activation by self nucleic acids.  At the same time, 
the surface-expressed TLR9 was no longer capable of recognizing genomic DNA 
from the virus HSV-2, presumably because this DNA was protected by the viral 
capsid when in the extracellular environment.  Thus, endosomal localization of 
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TLR9 not only prevented its  interaction with extracellular self DNA but also 
promoted its access to infectious viral DNA.  This latter point lends  support for 
the role of degradation in the lysosome (hypothesis 1, above).  Moreover, the fact 
that  surface-exposed TLR9 could effectively respond to low concentrations of 
DNA in the extracellular environment suggests that the ability to concentrate DNA 
(hypothesis 3) is not an essential role of the endosome for TLR9 function.  
Biology of endosomal TLRs: insights from autoimmune disease
Although sequestration of TLRs in endosomes appears to largely prevent self-
recognition, involvement of intracellular TLRs has been described in certain 
autoimmune pathologies. Antibodies that can bind chromatin, RNA and 
associated nucleoproteins form “immune complexes” that are characteristic of 
the autoimmune disease systemic lupus erythematosus (SLE).  Such immune 
complexes can be endocytosed via interaction with cell surface receptors  that 
recognize the Fc region of the antibodies, thus facilitating the uptake of 
complexed nucleic acids into endosomes and activation of innate antigen 
presenting cells48-50.  B lymphocytes express a specialized membrane-bound 
antibody known as the B-cell antigen receptor (BCR) and are able to recognize 
and endocytose immune complexes via BCR engagement. Synergy between 
BCR-derived and TLR7/9-derived signals are required for B-cell activation by 
nucleic acids51,52.  Immune complex diseases involve multiple types of immune 
cells and engage several signaling pathways.  Interestingly, there is  evidence 
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that interplay between nucleic acid sensing TLRs modulates SLE-like pathology 
in mice, with TLR7 generally exacerbating disease and TLR9 partially mitigating 
TLR7-mediated effects53.  Thus, understanding the interconnections between 
nucleic acid receptors and their modulation is a key step in preventing and 
treating certain types of autoimmunity.            
Signaling
Signaling pathways initiated by endosomal nucleic acid-sensing TLRs are 
common to all studied TLRs and are divided into two branches: the MyD88-
dependent and MyD88-independent pathways (Figure 1.1) The MyD88-
dependent pathway is used by all studied TLRs with the exception of TLR354,55. 
The pathway takes its  name from the essential role of the TIR-containing adaptor 
protein myeloid differentiation primary response gene 88 (MyD88), which 
associates via its TIR domain with the TIR domains of TLRs.  In the case of TLRs 
2 and 4, this  interaction is  bridged by another TIR-containing adaptor, MyD88 
adaptor like (MAL)56-58 *2 , while TLRs 5, 7-9 appear to associate with MyD88 
directly59-61.  Association of MyD88 with TLRs is followed by the recruitment of 
IL-1 receptor associated kinases (IRAK family members) to form a receptor 
complex known as the “Myddosome”61,62. IRAKs are then able to recruit the 
ubiquitin ligase TNF-associated factor 6 (TRAF6)59, which can activate the
14
*2  MAL is also called TIR domain-containing adaptor protein (TIRAP)
!"#
$%"&'
()*
$%"&+
,,%-"
.,%-"
!/..0
,012
!/344
$%"!
567 3-"
(19.:;0<=9>0?9>2,
@#"A!"!B!*%"-B
-3B CAC!B
$#%D
$#%E
$#%+
$#%F
$#%G
$#%'
$#%H
$#%4
$#%I
39:J/?:K2.
#960626K9.2,
$L9:J/?:K2.
#960626K9.2,
&?:M2??9>
#@A
$%(&
$*NF
%(@F
-&)*
-&)*
6L09>O?:11:K0L/ J/K0)9>2,
$/62P( (&-
(%&,
(%&,
G H+
Figure 1.1 Toll-like receptors, their ligands, and simplified signaling 
pathways. 
TLRs 1-2, 4-6 are expressed on the cell surface, while TLRs 3, 7-9 are 
expressed in intracellular compartments (TLRs 10-13 are not shown). Upon 
ligand binding, TLRs initiate signaling cascades involving the adaptor protein 
MyD88 (magenta and green lines) or the adaptor protein TRIF (orange lines). 
Dotted lines represent simplified pathways  with known intermediates. 
“Myddosome” refers to a multimolecular complex of MyD88 with varying 
combinations of IRAK1, IRAK2 and IRAK4.  For explanation of abbreviations 
please refer to the text and the List of Abbreviations. 
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transcription factor nuclear factor κB (NF-κB), mitogen-activated protein (MAP) 
kinases63 and interferon regulatory factor 5 (IRF5)64,65, leading to transcriptional 
upregulation of proinflammatory cytokines.  IRAK 1 activation can also lead to 
production of type-I interferon (IFN) via activation of TRAF666 and the related 
protein TRAF367, which activate other members of the IRF family of transcription 
factors.  
 The MyD88-independent signaling pathway used by TLR3 involves 
interaction of the TLR TIR domain with that of TIR domain-containing adaptor 
inducing interferon-beta (TRIF)68,69 *3 .  This leads to activation of TRAF3 and the 
Tank binding kinase 1 (TBK1) complex, which phosphorylates IRFs 3 and 7, 
resulting in upregulation of type-I IFN67.  TRIF can also activate the kinase 
receptor interacting protein 1 (RIP1), which leads to activation of NF-κB and 
transcriptional activation of proinflammatory cytokines70.  TLR4 also activates 
these TRIF-dependent signaling pathways, and associates with TRIF with the 
help of TIR-containing TRIF-related adaptor molecule (TRAM)71,72 *4 .  Hence, 
TLR4 is the only TLR which signals  through both MyD88 and TRIF, and requires 
the adaptors  MAL and TRAM in order to do so.  Because all known human and 
murine TLRs signal via MyD88 and/or TRIF, animals  doubly deficient in these two 
adaptor proteins55 are considered null for all TLR-based signals and these 
16
*3 TRIF is also called TIR domain-containing adaptor molecule 1 (TICAM1)
*4 TRAM is also known as TIR domain-containing adaptor molecule 2 (TICAM2)
animals are frequently used to distinguish TLR-mediated versus TLR-
independent responses to nucleic acids.     
Cytosolic nucleic acid sensors
Targeted delivery of nucleic acids to endosomes by immune complexes, viruses 
or cationic transfection agents is  an important safeguard in restricting the 
activation of nucleic acid-sensing TLRs.  However, many RNA and DNA viruses 
as well as certain bacterial pathogens penetrate directly into the cytosol of the 
cell.  It was soon recognized that the interferon-stimulating properties of nucleic 
acids described in the 1960’s could not be entirely explained by the action of Toll-
like receptors alone.  The identification of a cytosolic helicase protein that could 
activate interferon in response to RNA73 started off a second “boom” in nucleic 
acid sensing research, this time in discovery of soluble receptor proteins.  
RNA sensors
This  first recognized cytosolic sensor, retinoic acid inducible gene I (RIG-I) and 
the structurally homologous melanoma differentiation-associated gene-5 (MDA-5) 
are proteins containing an RNA-binding aspartate-glutamate-any amino acid-
aspartate/histidine-box (DExD/H-box, or simply DHX) helicase domain and two 
caspase activation and recruitment domains (CARDs)73,74, which were later 
found to interact with the mitochondrially-localized adaptor protein, mitochondrial 
17
antiviral signaling (MAVS)75-78 *5  (Figure 1.2). Both the helicase domain73 and the 
ability to interact with MAVS75 have been shown to be essential for type-I 
interferon activation.  A third member of this RIG-I like helicase (RLH) family, 
laboratory of genetics and physiology 2 (LGP2), can bind RNA by virtue of a 
helicase domain, but lacks CARDs to initiate downstream signaling74. Thus, is 
not considered a true RNA sensor, but it may serve to facilitate recognition of 
RNA by other RLH family members79.  RLH helicase domains can bind both ds 
and ssRNA and additional shared and distinguishing features of RLH ligands 
have been an active area of research.  While a number of distinct ligands have 
been described, current evidence suggests  that the optimal RIG-I ligand is blunt-
end 5‘ triphosphate-containing dsRNA (refer to 80 and references therein).  The 
ligands for MDA-5 and LGP2 remain largely undefined. 
DNA sensors
Similar to RLH, cytosolic receptors mediate responses to DNA in a manner 
independent of endosomal TLRs.  Several cytosolic DNA sensors have been 
described, and they can be grouped by the signaling pathways they activate 
(Figure 1.2):
18
*5 MAVS has also been named virus-induced signaling adaptor (VISA), interferon-beta promoter 
stimulator 1 (IPS-1) and CARD adaptor inducing interferon-beta (CARDIF). 
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Figure 1.2 Cytosolic nucleic acid receptors and simplified signaling 
pathways.  
Soluble receptor proteins recognize RNA (blue helices) or DNA (black helices) in 
the cytosol and initiate signaling cascades that converge upon activation of NF-
κB and IRF transcription factors  to promote the production of proinflammatory 
cytokines and type-I interferon.  For explanation of abbreviations please refer to 
the text and the List of Abbreviations.
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1. Receptors such as DAI81 *6  and IFI1682 induce expression of proinflammatory 
cytokines and type-I interferon upon DNA ligation through signaling pathways 
involving STING and either NF-κB (for proinflammatory cytokines) or IRFs (for 
    interferon).  
2. Helicases such as DHX9 and DHX36 interact directly with DNA and MyD88 
(see discussion of TLR signaling, above) to activate NF-κB and IRF783.  Thus, 
these cytosolic helicases appear to activate production of both 
proinflammatory cytokines and type-I IFN through MyD88-dependent but TLR-
independent pathways.  
3. RNA polymerase III (RNA pol III) reverse-transcribes certain types of dsDNA, 
such as AT-rich DNA, to an RNA ligand that activates RIG-I to induce 
expression of type-I IFN84,85.
4. Interferon induction in response to viral and bacterial DNA is  induced by 
leucine-rich repeat in Flightless I interacting protein-1 (LRRfip1) via activation 
of beta-catenin, which enhances IRF3 activation via a coactivator pathway 
involving CBP/p30086 *7.   
5.  Upon binding of DNA, the pyrin and HIN domain-containing receptor absent in 
melanoma 2 (AIM2), forms an inflammasome complex capable of activating 
the pro-inflammatory cytokine interleukin (IL)-1β87.        
20
*6 The role of DAI as a DNA sensor is somewhat controversial.  Although it was the first identified 
cytosolic DNA receptor, deficiencies in DNA sensing in DAI-knockout animals have not been 
clear.
7 It is also worth noting that LRRfip1 may sense dsRNA (refer to 259).
DNA ligands for these receptors are primarily double-stranded and rich in 
adenine and thymine bases.  Certain viral genomes and synthetic molecules 
have also been used to stimulate particular receptors.  However, the essential 
chemical characteristics of these ligands are yet to be clearly defined.  
Accessory molecules for intracellular nucleic acid sensors
A key task in understanding immunity is defining which proteins  are “essential” 
for a given recognition or signaling process and which ones exert enhancing or 
limiting effects.  The TLRs and most *8  cytosolic receptors mentioned heretofore 
are all “essential” in the response to particular ligands, though the consequences 
of their activation are sometimes redundant. Reductionist approaches have 
supplied us with a good understanding of the mode of action of these essential 
receptors.  However, as the naturalist John Muir has noted, “when we try to pick 
out anything by itself, we find it hitched to everything else in the universe”88. 
Nucleic acid receptors  are no exception to this axiom and several 
macromolecules have emerged as accessory factors that contribute to proper 
receptor function.  
21
8 To date, a complete functional deficiency in the absence of DAI, LRRfip1 or the DHX helicases 
has not been clearly demonstrated. 
 Though negative regulation is certainly important for controlling 
inflammatory reactions, such downregulation of nucleic acid sensors happens 
primarily at the level of receptor gene transcription or regulation of downstream 
signaling intermediates.  Here, I will focus on factors  that promote receptor 
activation via direct (or potentially direct) molecular interactions.  
 
Proteins that promote proper receptor localization
All TLRs are transmembrane proteins.  As such, they are synthesized on the 
membrane of the endoplasmic reticulum (ER) and then travel to other 
membrane-bound compartments or the plasma membrane via the cell’s vesicular 
transport network.  The proper folding of TLRs as they are synthesized in the ER 
has been shown to depend on the chaperone protein gp96 *9 .  Loss of gp96 
function ablates the ability of cells to respond to TLR ligands89, suggesting that 
creation of a TLR “stock” in the ER requires the help of this  chaperone.  Similarly, 
at least two ER-resident proteins  appear to be important for nucleic acid sensing 
TLRs to translocate from ER stores to endosomes.  Absence of the ER lumen 
protein associated with TLR4, A (PRAT4A) *10  appears to impede the ability of 
TLR9 to effectively translocate to the endosome90.  Cells  deficient in PRAT4A 
also showed decreased ability to respond to a TLR7 ligand, but not to a TLR3 
ligand90, suggesting that this protein may be key for transport of endosomal TLRs 
22
9 gp96 is also known as glucose regulated protein-94 kD (GRP94)
*10 PRAT4A is also called trinucleotide repeat-containing gene 5 (TNRC5)
that ultimately interact with MyD88, but is not essential for endosomal TLR 
trafficking that activates the TRIF-mediated pathway.  A membrane-embedded 
ER protein, UNC93B1, however, seems to be a master regulator of all ER-to-
endosome translocation.  A single point mutation in this protein keeps it from 
interacting with TLRs 3, 7 and 991, which confers a “triple deficient” (“3d”) 
phenotype in mice92.  Subsequent work has confirmed that UNC93B1 travels with 
TLRs from the ER to endosomes93 and that this protein may also exert other 
regulatory effects on endosomal TLR function94.  Beyond the fundamental ER-to-
endosome transport event, at least one protein may be necessary for mediating 
the translocation of TLR9 from a strictly endosomal compartment to a more 
mature endolysosomal compartment.  Adaptor protein 3 (AP3) is required for the 
production of type-I IFN but not for activation of NF-κB downstream of TLR9 in 
plasmacytoid dendritic cells (pDC), suggesting that distinct signals emanate from 
TLR9 depending on the maturity of the endosomal compartment in which it 
resides95.  However, further work has clarified that the peptide transport protein 
Slc15a4 may work upstream of AP-3 to maintain essential characteristics of 
acidfied compartments in pDC96, and thus  these two proteins may play distinct or 
overlapping roles in regulation of type-I IFN induction by endosomal TLRs.  
 Regulators of protein production and trafficking have not been clearly 
identified for cytosolic nucleic acid receptors and the roles  of such accessory 
molecules are likely to be forthcoming. 
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Cofactors that promote ligand-receptor interaction
TLRs expressed on the cell surface have a number of well-defined co-receptor 
molecules which facilitate their interactions  with ligands97, and many of these co-
receptors are essential for ligand recognition.  In contrast, no required co-
receptors have been recognized for endosomal TLRs, though several accessory 
molecules appear to enhance ligand:receptor interactions and/or signaling.  
 CD14 is  a required co-receptor for LPS and lipoprotein recognition by 
surface TLRs 2 and 498,99.  It exists in both membrane-anchored and soluble 
forms and both of these forms seem to be able to exert co-receptor function for 
surface TLRs.  Recent work has shown that CD14, while not strictly required, 
also serves as an important cofactor for endosomal TLRs100,101, where it appears 
to play roles  in ligand uptake and TLR recognition, as well as in enhancing 
downstream signaling101.  
 CD14 itself is not a signaling receptor; however, bona fide plasma 
membrane signaling receptors  have also been proposed to be important for the 
uptake of nucleic acid ligands into endosomal compartments.  These include 
several proteins  common on the surface of phagocytes, such as integrins and 
scavenger receptors102-104.  It thus appears clear that a variety of cell-surface 
proteins can bind nucleic acids and may promote their access to endosomal 
TLRs.  However, a lack of rigorous study of these nucleic acid:receptor 
interactions at the biochemical level, as well as  functional redundancy for nucleic 
acid uptake that keeps any single receptor from being considered “essential,” has 
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impeded these receptors from being considered an important component of 
nucleic acid sensing.  Thus, key roles of an “uptake receptor” for nucleic acids 
still remain to be identified.   
 In addition to membrane associated co-receptor molecules, regulatable 
soluble factors that bind nucleic acids have also been suggested to promote 
immune activation.  A cathelicidin antimicrobial peptide with an alpha-helical 
structure, LL37, has been shown to bind DNA and induce formation of 
multimolecular complexes105. This complexation seems to promote DNA 
endocytosis, thus enhancing DNA recognition by TLR9105.  A similar 
complexation effect is seen with the chromatin binding protein high mobility group 
box 1 (HMGB1)106 *11.  When released from cells under conditions of necrosis or 
cell stress, HMGB1-DNA complexes appear to interact with cell surface receptors 
including RAGE (this  receptor is  the focus  of the next section).  The DNA-TLR9 
co-receptor effects of both HMGB1 and LL37 have been shown primarily in 
plasmacytoid dendritic cells (pDC)105,106, the key cell type producing type-I IFN in 
both mice and humans. Interestingly, both LL37 and HMGB1 have been 
implicated in the enhancement of autoimmune syndromes (ref 107), suggesting 
that they are capable of making self DNA more immunogenic.  Natural cofactors 
that promote interaction of extracellular nucleic acids with cytosolic RNA and 
DNA receptors have not been described.  However, the fact that complexation of 
nucleic acids with synthetic transfection agents is  an effective mechanism for 
25
11 HMGB1 is also called amphoterin.
delivering immunogenic nucleic acids to cytosolic receptors suggests that natural 
factors with similar capabilities  could play important roles in promoting activation 
of these receptors.  Conversely, avoiding uptake of extracellular nucleic acids 
into the cytosol is likely an important mechanism for ensuring activation of these 
signaling pathways exclusively by viruses and intracellular pathogens.  This idea 
is  reinforced by studies showing that a deficiency of nucleases that degrade 
endogenous excesses of nucleic acids leads to the strong immunopathology 
seen in SLE108, Aicardi-Goutières syndrome and chilblain lupus109.  
 All together, our current understanding of the modulators of nucleic acid 
sensing suggest that the balance between limiting access of nucleic acids to 
intracellular sensors and facilitating this access is central to recognition of DNA 
and RNA by the immune system.             
RAGE
The term “pattern recognition receptor,” while often bringing to mind the well-
studied TLRs and RLRs, encompasses many receptor proteins that recognize 
ligands by means of conserved molecular patterns.  One lesser known PRR is 
the receptor for advanced glycation end-products  (RAGE).  This plasma 
membrane protein was initially thought to serve as a scavenger receptor that 
aided in the clearance of non-enzymatically glycated proteins  (advanced 
glycation end products, AGE) from blood serum (refer to 110).  While its role in 
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responding to AGE is an important one, this protein does not function specifically 
to clear these products from the circulation.  Instead, RAGE appears  to aid in the 
uptake and initiation of inflammation in response to the presence of AGE and a 
variety of other endogenously-derived DAMPs.  
 
Gene and protein
The location of the gene encoding RAGE, ager, in the human genome is 
suggestive of a function in immunity.  ager is located in the human leukocyte 
antigen (HLA) locus on chromosome 6, near the gene encoding major 
histocompatibility complex three (MHC III).  Structurally, RAGE belongs to the 
immunoglobulin receptor superfamily and has a conformation similar to that of an 
antibody heavy chain.  RAGE has three extracellular domains named according 
to their homology with immunoglobulin variable and constant regions, called V, 
C1 and C2 (Figure 1.3).  The RAGE “variable” domain does not vary in 
sequence, however, and recent work has suggested that this domain is more 
similar to those of adhesion molecules (also immunoglobulin superfamily 
members)111. Following a hydrophobic transmembrane domain is a short 
cytosolic tail consisting of just 41 amino acids and no clear signaling domains. 
This  full-length membrane-bound RAGE is just one of several naturally-occurring 
isoforms, which seem to number approximately 20 in humans112 and in mice113, 
though not all isoforms are shared between the two species113.  Defining a clear 
27
Figure 1.3 RAGE isoforms and ligands.  Established RAGE ligands are shown 
in cartoon form with the secreted, membrane-cleaved and membrane-bound 
isoforms of RAGE protein (green).  V- and C-type immunoglobulin-like RAGE 
domains are indicated on the cartoon and on the corresponding amino-acid 
sequence for membrane-bound RAGE.  Exon arrangement in cDNA of soluble 
and membrane-bound isoforms (based on 112) shows an area of alternative 
splicing resulting in an altered version of exon 9 (gray box) and an alternative C-
terminal amino acid sequence in the secreted protein.
28
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Figure 1.3 RAGE isoforms and ligands. 
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count of isoforms has been complicated by evidence that post-transcriptional 
control of RAGE varies across tissues and cell types and that several potential 
mRNA variants  are candidates for the nonsense-mediated decay pathway, and 
thus may never translate into functional proteins112,113.  That said, the two 
predominant forms of RAGE protein detectable in vivo are the full-length 
membrane-bound receptor described above, and soluble forms consisting of only 
the V-C1-C2 extracellular domains.  These soluble isoforms originate from two 
post-transcriptional processes: alternative mRNA splicing114-116 and cleavage of 
the membrane-bound protein by extracellular proteases117-119.  Because soluble 
RAGE (sRAGE) has the same ligand binding regions as  the membrane-bound 
form, it is  thought to function as an endogenous decoy receptor and this function 
has been exploited in experimental contexts  to block effects mediated by the 
transmembrane receptor.
RAGE ligands
RAGE:ligand interactions are thought to occur primarily with the outermost V 
receptor domain (this  topic is addressed in detail in Chapter II), and six families 
of ligands have been clearly established.  As previously mentioned, non-
enzymatically glycoxidated adducts on proteins were the first recognized RAGE 
ligands and were the basis for the receptor’s name120.  Many proteins can 
become covalently decorated with AGE moieties such as (carboxymethyl)
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lysine121 and pronyl-glycine122 when in the presence of aldose reducing sugars 
(i.e., glucose) in the bloodstream. Though not technically glycation products, 
oxidation products such as oxidized low-density lipoprotein (oxLDL)123 and 
advanced oxidation protein products  (AOPP)124 form under similar conditions as 
AGES and are also RAGE ligands.  Thus, AGEs are a heterogeneous class of 
endogenously-formed ligands. 
 The importance of RAGE as a true pattern-recognition receptor became 
more clearly defined as additional ligands were identified.  Fibrillar forms of 
amyloid-β were shown to interact with RAGE, which is  expressed on neurons 
and microglial cells in the brain125.  Both AGEs and amyloid plaques are 
materials  that can accumulate endogenously, and that require removal to 
maintain normal homeostasis.  Hence, RAGE seemed to play a role in detecting 
accumulations of toxic metabolic products.  This role broadened further with the 
identification of two other ligand classes: proteins of the high mobility group box 
(most notably HMGB1)110 and the S100 calcium binding proteins (specifically, 
S100A12 and S100b)126.  S100s and HMGB1 are not accumulated metabolites, 
but rather endogenous molecules  released from activated cells during 
inflammatory processes.  RAGE now appeared to be a key sensor of several 
homeostatic perturbations.  A specific role in inflammation was  further 
strengthened by the realization that RAGE could serve as a counterreceptor for 
β2 integrins, such as CD11b, through homotypic interactions, thus participating in 
the process of leukocyte recruitment127.  The most recently defined RAGE ligand, 
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extracellular DNA128 (also refer to 129 and data presented in chapter II), bolsters 
the case that RAGE is  integral to inflammation and tissue maintenance, as 
sensing of extracellular DNA is  a key mechanism for inducing immunity and 
tissue repair processes.  The interaction of RAGE with many of these ligands has 
been studied at the biochemical level and the available evidence indicates that 
RAGE interacts with these ligands directly.  However, potential roles of co-
receptors (refer to 130 and 131) have not been strictly interrogated and additional 
complexity may emerge to enrich our understanding of RAGE:ligand interactions.  
Signaling
The functional consequences  of ligand interactions  with RAGE have been a topic 
of intense interest. Early in its identification as the AGE receptor, RAGE was 
found to induce cellular changes consistent with a role as a signaling 
receptor132,133.  Subsequent work has begun to elucidate a complex network of 
signals that can be initiated by RAGE ligands and the majority of these pathways 
seem to converge, ultimately, on the activation of the transcription factor NF-κB 
(Figure 1.4).  As opposed to the relatively transient nature of NF-κB activation by 
other PRRs, RAGE-mediated signals seem to lead to a prolonged upregulation of 
NF-κB over periods of days or weeks, due in part to enhanced de novo synthesis 
of the transcription factor itself134, as well as increased receptor expression due 
to NF-κB activation of the RAGE promoter135.  The receptor-proximal factors that 
connect RAGE to activation of NF-κB include elements of several distinct
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Figure 1.4  Signaling pathways activated by RAGE.  Upon ligand binding, 
RAGE initiates distinct and intersecting signaling cascades to activate NF-κB and 
other transcription factors, as well as cytoskeletal remodeling.  Initiation of 
signaling may involve caveolin-1 (Cav-1) and diaphanous-1 (Dia1) as adaptors, 
or direct interaction of RAGE with downstream kinases and GTPases.  For 
complete explanation of abbreviations, please refer to the text or the List of 
Abbreviations. 
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Figure 1.4  Signaling pathways activated by RAGE. 
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signaling pathways and the pathway activated may depend to some extent on 
the type of cell expressing RAGE, as  well as  the ligand activating the receptor.  In 
several cell types, Rho-family GTPase proteins  Rac-1 and Cdc42 become 
activated by RAGE136-138. Once converted to their GTP-bound active state, these 
proteins have been shown to activate several different downstream kinases 
including the non-receptor tyrosine kinase Src and the serine/threonine kinase 
Akt138, to activate NF-κB.  These GTPases  have also been shown to activate the 
transcription factor activator protein 1 (AP-1) downstream of RAGE138, and to 
activate phosphatidylinositol 3-kinase (PI3K)138, which cause NF-κB independent 
effects.  Because activation of these GTPases incites rearrangements  of the 
actin cytoskeleton, RAGE stimulation has been implicated in cellular remodeling 
events such as migration137,139, neurite outgrowth136, and adhesion140, which play 
important roles in both homeostasis and immunity.  Outside of the Rho family, the 
related GTPase Ras is also activated downstream of RAGE141.  It is not entirely 
clear if this  activation results  directly from RAGE or from an increase in oxidant 
stress caused by other pathways activated by RAGE.  Ras downstream of RAGE 
leads to NF-κB p65 activation via the intermediate kinases MEK1 and p42/44 
ERK141,142.  There is also evidence that RAGE may be able to activate ERK and 
other kinases such as p38 MAPK142,143 and JAK2144 directly, without intervening 
G proteins.  The mechanisms by which this  could occur are not entirely clear, but 
ERK has been reported to induce NF-κB activation via phosphorylation of IκB 
kinase α/β (IKKα/β)145 and to interact directly with the cytosolic tail region of 
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RAGE146.  A cytosolic formin-homology domain-containing adaptor molecule, 
Diaphanous-1, also appears to directly interact with the  RAGE cytosolic tail, and 
this  interaction is essential for RAGE-dependent activation of Rho family 
GTPases137. Because Diaphanous-1 is known to interact with proteins that bind 
to the actin cytoskeleton137, this lends further evidence for a direct role of RAGE 
signaling in cellular remodeling.  Much remains to be clarified regarding how 
these pathways intersect functionally in distinct RAGE-expressing cell types. 
What is thus far clear is that both overtly immune effects such as cytokine 
production as well as more general effects  such as cell growth and motility are 
outcomes of RAGE:ligand interactions. 
 While a close association between RAGE signaling cascades and the 
cytoskeleton suggest that RAGE is  likely to traffic upon ligation of activating 
signals, the precise cell biology of this  process is incompletely described.  It has 
been shown that receptor internalization is an essential event for ERK activation 
downstream of RAGE in a neuroblastoma cell line147.  Additional insight comes 
from the observation that RAGE may interact closely with the structural 
component of membrane caveolae, caveolin-1, and that integrity of caveolae is 
required for both NF-κB and JAK-STAT activation by RAGE ligands in vascular 
smooth muscle cells148.  Collectively, these observations suggest that RAGE 
engages with extracellular ligands on the cell surface and mediates their uptake, 
via caveolae, into intracellular compartments, from which downstream signals 
can occur. 
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Expression in tissues and cells: complexity and ties to disease
The variety of RAGE signals and downstream functions take on an additional 
level of complexity when one considers the diversity of cell types in which RAGE 
is  expressed.  Studies of RAGE expression patterns in mammals suggest that 
there is very low, but constitutive, expression in most organs.  This seems to be 
attributable to expression by vascular endothelial and smooth muscle cells, which 
infiltrate all body tissues.  Unlike other adult tissues that have very little RAGE, 
the mammalian lung shows strong constitutive levels  of the receptor protein, 
which has been attributed to its expression primarily on type-I alveolar epithelial 
cells140,149.  RAGE has  been reported to be expressed on a number of 
leukocytes150-153, though it is not clear if this  expression is constitutive. 
Nevertheless, the signaling pathways shown to be activated by RAGE are 
common in many immune cell types, and such cells are often present at sites of 
accumulation of RAGE ligands, particularly HMGB1 and S100 proteins. Because 
leukocyte functions are closely associated with the endothelia and epithelia 
through which such cells extravasate, distinguishing between RAGE-mediated 
effects from leukocytes versus  ones originating from structural cells in vivo is  an 
interesting, important, and largely unexplored question.  Reductionist studies of 
cell lines  in vitro have yielded important insights into signaling pathways but stop 
short of assessing interactions between multiple cell types.  Conversely,  disease 
models  in vivo have indicated important RAGE-dependent phenotypes, but often 
yield little insight into the full interplay of mechanisms that lead to them.  Hence, 
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the tissue site of RAGE:ligand interaction is an open and intriguing question.  The 
immune/structural cell interplay is particularly interesting in light of the implication 
of RAGE in many pathologies that involve inflammation resulting in alteration of 
tissue structure, or vice versa.  These include lung diseases such as fibrosis, 
cancer, acute respiratory distress syndrome and certain infections149.  RAGE has 
also been associated with diseases of the vasculature that have an inflammatory 
component, including atherosclerosis, diabetic nephropathy and Alzheimer’s 
disease.  Animal models have implicated RAGE in a range of other inflammatory 
conditions including colitis, arthritis, microbial sepsis, and autoimmune 
syndromes such as experimental autoimmune encephalitis and multiple 
sclerosis154,155.  These studies provide strong evidence for the importance of 
RAGE in inflammatory syndromes and the need to identify and untangle the web 
of signals  across cell types  and tissues that RAGE may effect upon recognizing 
its array of ligands.
Thesis rationale, objectives, and summary
Nucleic acid sensing is currently a vibrant subfield of innate immunity research. 
Our laboratory has previously focused on the molecular and cellular biology of 
TLR9 and its  oligonucleotide ligands.  The mechanisms by which nucleic acid 
ligands placed into cell culture medium or injected into animals (i.e., extracellular 
nucleic acids) are taken up into TLR-containing intracellular compartments have 
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been a long-standing and largely unsolved point of interest.  In this context, and 
in the course of collaborative work on HMGB1, we discovered that the cell 
surface receptor RAGE could bind directly to TLR9-stimulatory oligonucleotides *. 
The research presented in this thesis  was designed to evaluate the role of RAGE 
in uptake and presentation of nucleic acids to endosomal receptors, as well as 
potential independent roles for RAGE as a nucleic acid sensor.  Chapter II 
presents extensive research into the chemical nature of nucleic acid ligands that 
bind to RAGE and the oligomeric nature of the receptor complex, the biology of 
RAGE:ligand uptake, and the manner in which RAGE enhances TLR9-mediated 
inflammatory responses to CpG DNA both in vitro and in vivo.  In physiological 
contexts, DNA is closely associated with another RAGE ligand, HMGB1, and the 
ways in which these two ligands and other multimolecular complexes interact 
with RAGE is explored in Chapter III.  Chapter IV considers how the data 
presented herein relate to previous knowledge about RAGE and other immune 
receptors, as well as implications for understanding larger questions of immunity 
and disease, and questions yet to be addressed.   
 This  work contributes to our understanding of the role of RAGE in 
modulating immune responses, particularly those initiated by nucleic acids.  As 
such, it provides an important link in conceptualizing how RAGE contributes to 
immune complex-forming autoimmune diseases and inflammatory pathologies of 
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* At the time, DNA as a RAGE ligand was not yet mentioned in the scientific literature.
the lung, as well as designing precise biopharmaceutical therapeutic agents for 
their treatment and prevention.              
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CHAPTER II: RAGE recognizes nucleic acids and promotes 
inflammatory responses to DNA
Abstract
Nucleic acids are sensed by the immune system during infections and tissue 
damage.  Activation of the endosome-resident signaling receptors is critically 
limited by restricting the access of nucleic acids  from the extracellular space. 
Here we show that the receptor for advanced glycation end-products (RAGE) 
promoted DNA uptake into the endosomal network and lowered the threshold for 
activation by DNA. Structural analysis indicated that DNA interacted with dimers 
of the outermost RAGE extracellular domains, and could induce formation of 
higher-order RAGE complexes.  Mice deficient in RAGE were unable to mount a 
typical inflammatory response to CpG DNA in the lung, indicating that RAGE is  a 
key component in fine-tuning interaction of nucleic acids with their sensors.   
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Introduction
Infection and tissue damage cause an immediate inflammatory response that is 
characterized by the activation of local structural cells  and innate immune cells 
and by rapid recruitment of additional immune cells to the affected site. This 
response serves to control the invading pathogen and to initiate reparative 
processes that restore tissue function.  However, the inflammatory process must 
be well balanced, as an exaggerated immune response may result in collateral 
tissue damage.  
 In the last decade, much has been learned about the molecular 
mechanisms that orchestrate inflammatory responses. The immune system 
becomes activated when any of a diverse array of receptor proteins engages its 
respective ligand molecule(s). These ligands  may originate either from an 
infectious microbial source or from the host itself, under conditions of cell stress 
and tissue damage. Under normal homeostatic conditions, such immune triggers 
are absent or scarce in the host or are sequestered so as to prevent access  to 
compartments containing signaling receptors.  Immunity-triggering molecules 
take a number of distinct chemical forms, which are recognized by several 
families of germline-encoded innate immune signaling receptors expressed either 
on membranes156 or in the cytosol157.  Certain surface-exposed immune 
receptors recognize a number of lipidated or proteinaceous activators that are 
foreign to the host, such as lipopeptides (Toll-like receptor (TLR)2), 
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lipopolysaccharides (TLR4), and flagellin (TLR5). In contrast, many signaling 
receptors do not have immediate access to the extracellular space, as they are 
expressed in the endoplasmic reticulum and endosomal membranes (TLR3, 7, 8 
and 9) or in the cytosol (RIG-I like receptors, AIM-2, and as-yet undefined DNA 
sensors).  Indeed, all described immune sensors devoted to the recognition of 
nucleic acids are expressed in compartments that are sequestered away from 
the extracellular milieu.  
 Nucleic acids present a unique challenge to the immune system: on one 
hand, sensing of microbial genetic materials  is an efficient way to detect viruses 
and other types of invading pathogens. However, mechanisms must exist for 
distinguishing such exogenous  nucleic acids from the host’s own DNA and RNA. 
Sequestration of nucleic acid sensing receptors has been proposed to limit 
receptor triggering by self nucleic acids that are present in the extracellular space 
under homeostatic conditions, presumably due to normal cell turnover.  Indeed, 
experimental mis-localization of TLR9, an endosomal receptor for DNA, to the 
plasma membrane led to the recognition of self-DNA from the extracellular 
environment42. At the same time, endosomal localization of TLR9 was required 
for efficient recognition of viral DNA42, suggesting that nucleic acids become 
concentrated in endosomal compartments  or that additional mechanisms of 
receptor processing are required for nucleic acid recognition in the 
endosome45,158,159. 
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 Along with compartmentalization, other safeguards  typically prevent self 
nucleic acid recognition by innate immune receptors. For example, nucleases 
present in the extracellular space (DNAse I), in endosomal compartments 
(DNAse II) and in the cytosol (DNAse III) digest DNA and ensure that DNA 
released under normal conditions escapes detection by nucleic acid 
sensors160-164.  However, if nucleic acid concentrations exceed the nuclease 
capacity, such as during infections  or in situations of increased cell damage, 
signaling receptors and their downstream inflammatory effects can be triggered. 
Chronic activation of inflammatory responses by nucleic acids can result in 
undesirable autoimmune syndromes and dramatic pathologies164,165, yet the 
recognition of DNA during tissue destruction is an integral part of the host 
immune and repair responses166.  Hence, effective management of self-tolerance 
and damage sensing appears to require the coordinated delivery of extracellular 
DNA to intracellular sites of recognition. 
 Here, we identify the receptor for advanced glycation end-products 
(RAGE) as a cell surface receptor for nucleic acids.  RAGE binds directly to DNA 
and RNA and promotes their uptake into endosomal compartments, thereby 
sensitizing cells  to extracellular nucleic acids. A co-crystal structure of RAGE with 
DNA supports the concept that RAGE binds to nucleic acids via interaction with 
the charged sugar-phosphate backbones in a sequence-independent manner. 
RAGE deficiency largely prevents  an inflammatory response towards TLR9 
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stimulatory DNA in the lungs, suggesting that RAGE plays an important role for 
the recognition of DNA in vivo.
Results
RAGE concentrates DNA on cells and interacts with DNA in a sequence-
independent manner.
To address  the role of RAGE in cellular responses to DNA, we generated cell 
lines expressing chimeric fluorescent RAGE driven by a tetracycline-inducible 
promoter. Uninduced cells  did not show significant RAGE expression and we 
observed only a low amount of DNA binding to the cells (Figure 2.1a). RAGE-
mCitrine expression was approximately 100-fold higher after promoter induction 
and RAGE-expressing cells bound 10- to 100-fold more fluorescently labeled 
DNA compared to uninduced cells  (Figure 2.1a). In addition, the amount of DNA 
binding correlated directly with the level of RAGE expression (Figure 2.1a). 
Notably, when incubated with fluorescently labeled DNA and visualized by 
confocal microscopy, cells  expressing RAGE had visibly more DNA bound at the 
cell surface than cells  not expressing RAGE (Figure 2.1b). These data 
suggested that RAGE interacts with and concentrates DNA on cell surfaces. 
 We next sought to identify the characteristics of RAGE-binding nucleic 
acids. We found that several structural classes of CpG oligonucleotides, which 
are known to activate TLR9167, bound to purified RAGE protein with low 
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Figure 2.1  RAGE binds directly to nucleic acid ligands on the cell surface. 
(a) 293T cells expressing tetracycline-inducible RAGE-mCitrine were left 
uninduced (left panel, black population) or treated to induce RAGE expression 
(right panel, black population) and then incubated on ice with 1 µM AlexaFluor 
647-labeled ODN 2336 (CpG-A, red populations), washed, and analyzed by flow 
cytometry. (b) HeLa cells  expressing Rab 4a-YFP (red) to visualize the 
cytoplasm, with or without coexpression of RAGE-YFP (green), were incubated 
with 1 µM AlexaFluor 647-labeled ODN 2336 (CpG-A, blue; white in small panel 
for better viewing) for 5 minutes.  Excess DNA was washed away and live cells 
were imaged by confocal microscopy. White arrows indicate RAGE-positive cells 
exhibiting DNA binding at the cell surface. (c) Ability of purified, his-tagged 
human RAGE extracellular domain to bind to biotinylated oligonucleotide ligands 
in solution was  assessed by AlphaScreen homogenous binding assay.  Indicated 
concentrations of oligodeoxynucleotides (ODN) or oligoribonucleotides (ORN) 
were incubated with 40 nM RAGE (V-C1-C2)-his.  PO, phosphodiester-linked 
deoxyribose backbone; PS, phosphorothioate-linked deoxyribose backbone.
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nanomolar affinities (Figure 2.1c). However, in contrast with previous findings128, 
oligodeoxynucleotides (ODN) bound RAGE in a sequence-independent manner 
(Figure 2.2a) and even phosphodiester and phosphorothioate sugar-phosphate 
backbones without nucleotide bases bound to RAGE with apparent high affinities 
(Figure 2.1d). We observed similar binding affinities for single-stranded (ss) and 
double-stranded (ds) forms of DNA (Figure 2.2b) and RAGE was able to bind 
ODN as short as  15 bases in length (Figure 2.2c). In addition, we found that 
RNA could interact with RAGE at apparent high affinity (Figure 2.1e). These 
studies indicated that nucleotide bases play a minimal role in DNA binding and 
that RAGE may bind to nucleic acids by interaction with the sugar-phosphate 
backbones. 
RAGE binds DNA through electrostatic attractions with the backbone
The RAGE extracellular region is composed of three structural domains named 
according to their homology to other members of the immunoglobulin 
superfamily: an N-terminal variable-type (V) (or I-type, refer to 111) domain, 
followed by two membrane-proximal constant-type domains (C1 and C2).  The V 
and C1 domains  are thought to form a single structural unit, which is separated 
from the C2 domain by a flexible linker region168. To assess which part of RAGE 
interacts with DNA, we investigated DNA binding to recombinant V domain, V-C1 
domains or C1-C2 domains, respectively. DNA binding was mediated primarily by 
the outermost V domain of RAGE (Figure 2.3a), similar to what has been
48
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Figure 2.2  Additional binding data: RAGE binds directly to oligodeoxy-
nucleotides of distinct sequences and sizes.  
Indicated concentrations of ODN were incubated with 40 nM his-tagged RAGE 
V-C1-C2 and binding was assessed by AlphaScreen.   Binding was tested for (a) 
homopolymers consisting of 24 nucleotides of adenosine (A), thymine (T), 
cytosine (C) or guanine (G) with a phosphodiester backbone (PO); (b) single-
stranded 24-mer ODN 2006 with a phosphodiester backbone (black circles) and 
the same oligo annealed to its  complementary strand (blue squares); (c) full 
length ODN 2006 with a phosphodiester backbone (2006-PO-24mer) and with 
forms of the same ODN truncated from the 3’ end; (d) the double-stranded 
phosphodiester-backbone vaccinia virus-derived DNA sequence (752/753-
PO-22mer) used in the co-crystal. Single stranded 2006-PO-24mer is shown for 
reference.
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Figure 2.3a-b  DNA interacts with a region of positive charges at the RAGE 
dimer interface.  
(a) Binding in solution of biotinylated ODN 2006 (CpG-B) to full length human 
RAGE extracellular domain (V-C1-C2-his) or isolated structural domains was 
evaluated by AlphaScreen homogenous binding assay. Indicated concentrations 
of CpG-B were incubated with 40 nM RAGE.  (b) Electrostatic charge surface of 
RAGE is shown on a scale of -10 kT/e (red) to +10 kT/e (blue) in three different 
orientations. The bound dsDNA is shown as an orange ribbon. 
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Figure 2.3c-d  DNA interacts with a region of positive charges at the RAGE 
dimer interface.  (c) Surface representation (center) showing positively charged 
residues lining the RAGE dimer interface where DNA binding occurs.  DNA-
binding residues are colored green on one RAGE molecule (“molecule A” in the 
text) and cyan on the other (“molecule B” in the text). Side panels show the 
molecular details of the two discrete binding sites, indicated by red boxes, for 
each RAGE V-C1 domain colored green and cyan.  Hydrogen bonds are 
indicated with dotted lines, and the two strands of the dsDNA are colored silver 
and yellow, respectively. (d) Polyethyleneimine (PEI) competes with RAGE for 
binding to CpG-B (PO and PS backbones), CpG-A and CpG-C.
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Figure 2.3c-d  DNA interacts with a region of positive charges at the RAGE 
dimer interface. 
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reported for binding of other RAGE ligands129,168,169.  The C2 domain did not 
directly bind DNA in our assays (Figure 2.3a and data not shown), but may 
enhance ligand binding by promoting proper folding and charge relationships 
throughout the extracellular domain, as DNA binding to V-C1-C2 appears to be 
more favorable than to V-C1 alone. 
 To understand the molecular details of the RAGE:DNA interaction, we 
determined the crystal structures of the RAGE V-C1 domain in complex with a 22 
nucleotide dsDNA molecule derived from vaccinia virus genomic repeat 
sequences and a 22mer CpG motif-containing dsDNA molecule, at resolutions of 
2.8 Å and 3.1 Å, respectively (Table 2.1 and Figure 2.4a).  As the structures 
were essentially the same except for the two dsDNA sequences, the following 
discussion will focus on the higher resolution 2.8 Å structure. The structures  were 
solved by molecular replacement using two previously published RAGE V-C1 
domain structures (PDB accession numbers 3CJJ111 and 3O3U129) as the search 
models. The structures revealed that the RAGE V-C1 domains formed a 
homodimer with the dsDNA bound in a concave cradle near the dimer interface 
(Figure 2.3b). The two V-C1 monomers interacted with each other in a dyad 
configuration with their V domains located at the dimer interface (see below), 
creating an extensive positively charged pocket where dsDNA binds.  Excellent 
charge and shape complementarity were observed between the RAGE interface 
and the bound dsDNA. Close examination of the protein:DNA interaction surface 
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Table 2.1  X-ray crystallography data collection and refinement statistics.
  I (752-753, VV) II (981-982, CpG)
Data Collection
        Spacegroup P61 P61
Unit cell (a, b, c) (Å) 79.12, 79.12, 224.04 77.92, 77.92, 224.39
(α, β, γ) (°) 90, 90, 120 90, 90, 120
Wavelength (Å) 1.00 1.00
Resolution (last shell) (Å) 50-2.80 (2.85-2.80) 50-3.10 (3.15-3.10)
No of reflections (total/
unique)
154198/19330 138765/13817
Completeness (last shell) 
(%)
99.4 (96.6) * 99.0 (85.6) *
I/s(I) (last shell) 14.49 (1.97) * 16.10 (1.97) *
Rmerge (last shell) (%)¶ 10.7 (60.7) * 14.0 (65.3) *
Refinement
Number of protein atoms 3267 3274
No. of DNA base pairs 22 22
No. of solvent/hetero-atoms 75 61
Rmsd bond lengths (Å) 0.007 0.008
Rmsd bond angles (°) 0.982 0.975
Rwork (%)† 19.6 19.1
Rfree (%)‡ 23.8 23.1
Ramachandran plot 
        favored/disallowed (%) **
95.7/0 95.7/0
PDB accession code 3S59 3S58
*Asterisked numbers correspond to the last resolution shell.
¶ Rmerge = ∑h ∑i |Ii(h) -<I(h)> | / ∑h∑i Ii(h), where Ii(h) and <I(h)> are the ith and 
mean measurement of the intensity of reflection h.
† Rwork = ∑h||Fobs (h)|-|Fcalc (h)|| / ∑h|Fobs (h)|, where Fobs (h) and F calc (h) are the 
observed and calculated structure factors, respectively.  No I/σ cutoff was 
applied. 
‡Rfree is the R value obtained for a test set of reflections consisting of a randomly 
selected 5% subset of the data set excluded from refinement.
**Values from Molprobity server (http://molprobity.biochem.duke.edu/)
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Figure 2.4  Additional data: RAGE binds dsDNA at the dimer interface. 
(a) On the left, refined 2Fo-Fc map for the dsDNA is shown as magenta mesh 
superimposed on the refined model. On the right, the top 10 molecular 
replacement solutions  for the dsDNA are shown as orange ribbons, with the 
refined dsDNA in red ribbon. (b) Footprint of the RAGE dimer on the dsDNA 
colored cyan and green for each of the V-C1 domains. (c) The two RAGE V-C1 
molecules (cyan and green) in the crystal are superimposed with their bound 
dsDNA (blue and green), showing the switched positions for the major and minor 
grooves of the dsDNA in reference to the V-C1 domains. (d) The RAGE dimer 
interface centered at the V domain. Residues involved in RAGE dimerization are 
shown as sticks and colored cyan and green as the respective molecules. Water 
molecules are shown as red spheres and hydrogen bonds as dotted lines. The 
crystallographic dimer from 3CJJ is superimposed in our DNA-bound RAGE 
dimer structure in wheat and orange.
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Figure 2.4  Additional data: RAGE binds dsDNA at the dimer interface.
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indicated that ~7 positively charged residues on each V-C1 unit were in close 
proximity to the negatively charged DNA backbone, spanning ~17 bp (Figure 
2.3c and Figure 2.4b), in agreement with our finding that the minimal length 
requirement for DNA binding was approximately 15 bases (Figure 2.2c). Each of 
the RAGE V-C1 domains  engage both strands of the dsDNA through basic or 
hydrophilic residues from RAGE interacting with oxygen atoms of the DNA 
backbone and, in some cases, through coordinating water molecules. 
 A total of 1300 Å2 of solvent accessible surface area was buried at the 
RAGE:DNA interface. There are two DNA binding patches on each RAGE 
molecule, hereafter referred to as “site 1” and “site 2” (Figure 2.3c). Site 1 is 
located entirely in the V domain near β-strand B (βB) and the connecting loops 
containing residues K37, K39 and K43, as  well as K107 from β-strand G. 
Notably, residues  K43 from molecule A and R29 from molecule B coordinate the 
same water molecule (w26) that forms a hydrogen bond with an oxygen of the 
DNA phosphate backbone (Figure 2.3c upper right panel). Site 2 is located at 
the juncture of the V and C1 domains, and includes residues R29 at the C-
terminus of βA, Y118 and K123 of the V-C1 linker, and R216 and R218 of βG in 
the C1 domain.  The amide group of R218 forms a direct hydrogen bond with a 
backbone oxygen of DNA (Figure 2.3c bottom right panel). The footprints of the 
two RAGE molecules  on the dsDNA are very similar but not identical (Figure 
2.4c), with the dsDNA switching its location of the major and minor grooves 
relative to the RAGE molecules, suggesting a rather flexible surface of the RAGE 
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dimer that may be able to accommodate various forms of nucleic acids such as 
ds or ss DNA and RNA. This is consistent with the dominant presence of flexible 
lysine and arginine residues at the DNA binding surface. 
 In contrast to sequence-specific DNA recognition by proteins  such as 
transcription factors, the current structures showed no contact between RAGE 
and the nucleotide bases. Because the overall negative charge on the DNA 
molecule is determined by its  phosphate backbone, we tested whether cationic 
polymer polyethyleneimine (PEI) could compete with RAGE for DNA binding. 
Our results  showed that PEI could “mask” the negative charge of DNA and was 
sufficient to negate DNA:RAGE binding in vitro (Figure 2.3d), further highlighting 
the electrostatic nature of the recognition.
 No major conformational changes were observed in the RAGE V-C1 
domains between the DNA-bound structures and those of the non-DNA bound 
forms (3CJJ129 and 3O3U111; Figure 2.5a), consistent with the observation that 
the linkage between the V and C1 domains is fairly rigid168 and is  not modified by 
the binding of DNA ligands.
Dimerization of the RAGE V-C1 domains 
A hydrophobic surface on the V domain is located at the center of the RAGE 
dimer interface in the current configuration we call “trans.” It is  composed of 
residues L79, P80, F85, P87, and A88 from the βE strand and the connecting 
loops, plus P33 and V35 from the βB strand, and P45 and P46 from the βB-βC 
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loop (Figure 2.4d and Figure 2.5a).  The hydrophobic patch is surrounded by 
hydrophilic residues decorating the circumference of the dimer interface.  A 
previous structure of RAGE V-C1 in the absence of bound DNA showed a 
crystallographic C1-C1 dimer that we call “cis,” which is centered at a bound zinc 
ion111. In comparison with the V domain-centered trans dimer interface, the cis 
dimer interface is hydrophilic and smaller in size. Unexpectedly, examination of 
the 3CJJ crystal lattice packing revealed that the trans dimers are also present in 
this  crystal (Figure 2.5a), though the DNA binding site is  occluded by 
crystallographic symmetry mates. It is  thus clear that the trans dimer formation is 
independent of DNA binding, and both the trans and the cis  dimers can co-exist 
as in the 3CJJ crystal.  This is consistent with our observation that the most 
intense fluorescence of RAGE on the cell surface is located at the juncture of two 
adjacent cells (Figure 2.5e, Figure 2.8c), indicating that both trans and cis 
dimerization may be involved in the formation of the RAGE oligomers, with the 
cis  and trans configurations mediating RAGE interaction on the same cell and 
adjacent cells, respectively.
 The chemical nature of the trans dimerization interface, including a typical 
buried solvent-accessible surface area of over 1000 Å2, together with the 
observations that RAGE V170, V-C119, or V-C1-C2171 domains spontaneously 
dimerize in solution, suggests  that the V-domain mediated dimers are likely to be 
present under physiological conditions.  As RAGE molecules are highly
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Figure 2.5  Constitutive RAGE dimers form higher order oligomers in the 
presence of complex DNA ligands. (a) Ribbon diagrams of the RAGE V-C1 
dimerization interface.  Left, RAGE V-C1 crystal packing in the non-DNA bound 
form (3CJJ)1, with V-C1 monomers colored yellow, orange, and wheat. The 
orange sphere indicates a zinc ion.  Middle, wheat and orange V-C1 domains 
from the left superimposed onto the V-C1 domains  (cyan and green) in the 
current DNA-bound crystal structure. The dimer interface at the V domain (red 
circle) is represented in gray surface (right), with the hydrophobic and hydrophilic 
residues colored orange and green, respectively. (b) HEK293 cells  expressing 
RAGE-mCitrine were incubated with or without the amine-reactive crosslinking 
agent BS3 prior to immunoblot for the mCitrine tag.  (c) HEK293 cells co-
expressing RAGE-CFP and RAGE-YFP were analyzed for FRET by flow 
cytometry.  Cells  show detectable baseline FRET (black histogram) in the 
absence of ligand. Cells  expressing only RAGE-CFP (FRET-negative, gray 
histogram) are shown for reference. (d) Cells from (c) were incubated with the 
indicated concentrations of oligonucleotides and analyzed for FRET by flow 
cytometry.  Graphs show the percent increase in FRET signal over baseline 
FRET.  “x2” indicates biotinylated ODN  complexed with streptavidin in a 2:1 
ratio. (e) HEK293 cells  co-expressing RAGE-mCerulean and RAGE-mCitrine 
were incubated for 30 minutes at 37 ºC with AlexaFluor 647-labeled CpG-A or 
CpG-B and analyzed for FRET by confocal microscopy.  FRET efficiency in 
individual cells is plotted, with lines indicating the mean value for each condition.
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Figure 2.5  Constitutive RAGE dimers form higher order oligomers in the 
presence of complex DNA ligands. 
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conserved in both their DNA binding sites and dimerization sites (Figure 2.6), 
RAGE dimer binding to nucleic acids through electrostatic attraction may be a 
common mode of its function in different species. 
 
DNA can induce formation of higher-order RAGE oligomers 
 To confirm RAGE dimer and oligomer formation in live cells, we subjected 
293T cells expressing full-length human RAGE-mCitrine to treatment with the 
cell-impermeable crosslinking agent BS3, followed by cell lysis, protein 
denaturation and gel electrophoresis.  In the presence of crosslinker, higher 
molecular weight bands corresponding to dimers and higher-order oligomers can 
be detected in unstimulated cells (Figure 2.5b). To further explore the 
relationship of native RAGE dimers with DNA ligands, we generated dually-
labeled cell lines appropriate for Förster resonance energy transfer (FRET) 
studies.  HEK293 cell lines stably expressing RAGE tagged with FRET donor 
(CFP or mCerulean) and acceptor (YFP or mCitrine) fluorophores were analyzed 
by both flow cytometry and confocal microscopy for energy transfer between 
fluorophore tags. A constitutive baseline energy transfer was observed in 
unstimulated cells (Figure 2.5c, Fig 2.5e, top panel), supporting the idea that 
RAGE exists as a dimer in the absence of ligand.  Addition of a CpG-B 24-mer 
oligonucleotide did not alter energy transfer efficiency (Figure 2.5d, left panel, 
Figure 2.5e, middle panel).  Interestingly, however, the addition of a CpG-A 21-
mer induced a dose-dependent increase in FRET efficiency (Figure 2.5d, left 
62
Figure 2.6  Sequence alignments of selected RAGE V-C1 domains. The β 
strands and 310 helices are labeled atop the sequences, with those for V 
domains noted with “I” and C1 domains “II”. The residues at the trans dimer 
interface are colored orange and green for hydrophobic and hydrophilic 
interactions, respectively. The DNA binding residues are shown in red boxes. The 
two disulfide bonds are shown as “SS1” and “SS2”, respectively.
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panel).  CpG-A oligonucleotides  are able to adopt large complexes in solution by 
virtue of G-tetrad formation between poly-G tails  on the ends of the ODN172.  The 
induced increase in FRET is  consistent with higher-order RAGE oligomer 
formation.  In keeping with this  observation, CpG-A DNA can be seen to induce 
aggregation of RAGE into clusters on the cell surface (Figure 2.5e, bottom 
panel), which is not observed in unstimulated cells or cells incubated with CpG-B 
(Figure 2.5e, top and middle panels).  Simply increasing the length of the DNA 
ligand did not promote increased energy transfer (Figure 2.5d, right panel), nor 
did complexation of short, biotinylated ODN sequences with streptavidin (Figure 
2.5d, left panel).  However, biotin-streptavidin complexation of a relatively long 
ODN increased FRET efficiency (Figure 2.5d, right panel). These findings 
suggest that while RAGE may bind DNA indiscriminately, only large ligand 
complexes induce receptor reorganization on the cell surface.  
RAGE expression promotes DNA uptake by cells via the endosomal route
 Having established that RAGE and DNA interact at the cell surface, we 
sought to understand the functional consequences of this  interaction.  Cells 
expressing RAGE not only showed increased binding of both CpG-A and CpG-B 
DNA to the cell surface, but also a notable increase in total DNA uptake over a 30 
minute time period (Figure 2.7a), compared to cells  not expressing RAGE.  This 
effect was DNA-specific, as binding and uptake of transferrin to its  respective 
receptor (Figure 2.7a) or the uptake of TLR2 ligand (not shown) was not 
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Figure 2.7  RAGE promotes cellular DNA uptake. (a) 293T cells expressing 
tetracycline-inducible RAGE-mCitrine were induced overnight (black bars) or left 
untreated (white bars) and then incubated with 1µM AlexaFluor 647-labeled 
transferrin, CpG-A or CpG-B at the indicated temperatures for 30 minutes, 
washed to remove unbound DNA, and analyzed by flow cytometry. Error bars 
indicate standard error of the mean. (*) Indicates  p <0.05 as  assessed by two-
tailed t-test. (b-c) HeLa cells  expressing RAGE-CFP (green) and the early 
endosome protein Rab 5a-RFP ((b), red) or the late endosome protein Rab 9a-
YFP ((c), red) were incubated with 1 µM AlexaFluor 647-labeled CpG-A or CpG-B 
for 5 minutes, washed to remove unbound DNA, then incubated for the indicated 
times at 37 ºC prior to analysis by confocal microscopy.  Bar graphs show the 
percentage of Rab-positive endosomes colocalizing with both the RAGE and 
DNA tags at each time point.  Error bars indicate standard error of the mean.
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Figure 2.7  RAGE promotes cellular DNA uptake. 
67
influenced by RAGE expression.  CpG DNA in cell culture medium gains access 
to endosomal compartments, where it is  able to interact with and stimulate Toll-
like receptor 9 (TLR9), although the mechanism by which this uptake occurs  is 
unknown.  While cellular uptake of DNA is not strictly RAGE-dependent (Figure 
2.7a), we sought to evaluate the nature of the receptor-ligand association after 
surface binding.  We stably expressed fluorescently tagged RAGE together with 
fluorescently tagged endosomal markers and assessed the binding and 
trafficking of DNA in live cells. Fluorescently labeled DNA was seen to associate 
with RAGE at the cell surface and traveled together with the receptor into both 
early and late endosomal compartments (Figure 2.7b-c).  Notably, the kinetics of 
trafficking differed depending on DNA ligand structure. While CpG-B entered the 
cell quickly and could be found in late endosomes 20 minutes after exposure, 
RAGE:CpG-A clusters persisted longer at the cell surface and remained primarily 
in early endosomes at 20 minutes  (Figure 2.7b-c).  By 90 minutes, both CpG-A 
and CpG-B could be seen colocalized with RAGE in late endosomes (Figure 
2.7c), the compartment from which TLR9 is thought to signal39,173.  Hence, RAGE 
and DNA appear to remain associated during uptake and progression through 
the endosomal network, and the trafficking kinetics is influenced by the DNA 
structure and, potentially, the ability of these ligands to multimerize RAGE. 
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RAGE increases TLR9-dependent responses to suboptimal DNA stimuli
 Both RAGE and TLR9 have been shown to activate the NF-κB family of 
transcription factors  upon ligation of stimulatory ligands34,133.  To assess the 
ability of CpG DNA to activate RAGE signaling, we employed an HEK cell line 
expressing a luciferase reporter gene under the control an NF-κB-inducible 
promoter.  No significant reporter activation was observed upon DNA stimulation 
when these cells overexpressed RAGE alone (data not shown).  A stable cell line 
expressing TLR9 together with TLR2 and tetracyline-inducible RAGE was 
established to evaluate the ability of RAGE to contribute to TLR9-dependent 
CpG-B responses.  Two different length CpG-B oligonucleotides, which are 
optimal for stimulation of NF-κB via TLR9, activated NF-κB in a dose-responsive 
manner in cells expressing TLR9/2 without RAGE, and this activation was 
notably enhanced when RAGE expression was induced (Figure 2.8a, left panel). 
This  RAGE-dependent enhancement was specific for DNA, as co-expression of 
RAGE did not alter NF-κB activation in response to the TLR2 ligand Pam3CysK4 
(Figure 2.8a, right panel).  We next sought to understand whether RAGE could 
similarly affect responses to mammalian DNA.  For this, the luciferase reporter 
cell line was co-cultured with immortalized murine bone marrow-derived 
macrophages and treated with silica to induce macrophage cell death.  Silica 
treatment of luciferase reporter cells  alone did not induce significant NF-κB 
activation (data not shown). The presence of silica-killed macrophages in co-
culture activated NF-κB and this activation increased in cells expressing RAGE 
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Figure 2.8  RAGE increases TLR9-dependent NF-κB activation in response 
to DNA ligands. (a) HEK293 cells expressing TLR9, TLR2, tetracycline-inducible 
RAGE and firefly luciferase under the control of the NF-κB-inducible ELAM 
promoter were treated with doxycycline to induce RAGE expression and then 
stimulated with CpG-B or Pam3CysK4 at the indicated concentrations for 12 
hours prior to measurement of luciferase protein. (b) HEK293 cells expressing 
TLR9 and tetracycline-inducible RAGE-mCerulean ELAM-luc reporter were 
cultured with or without doxycyline to induce RAGE expression, together with 
murine bone marrow-derived macrophages.  Co-cultures were left unstimulated 
or stimulated with silica crystals  to induce macrophage cell death.  Degradation 
of the phosphodiester (PO) CpG-B DNA stimulus served as a positive control for 
benzonase activity.  Error bars indicate standard deviation. (c) Co-cultured cells 
from (b) were incubated with silica for 6 hours, stained with propidium iodide to 
label DNA from dead cells, and imaged by confocal microscopy. Silica was 
visualized using a reflection microscopy technique1.
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Figure 2.8  RAGE increases TLR9-dependent NF-κB activation in response 
to DNA ligands.  
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(Figure 2.8b).  Treatment of co-cultures with benzonase to degrade extracellular 
DNA and RNA decreased the ability of dead macrophages to stimulate reporter
cells, suggesting that enhancement of activation by RAGE is due largely to 
recognition of nucleic acids (Figure 2.8b).  In effect, DNA from dying 
macrophages was  seen interacting with RAGE when cocultured cells  were 
imaged by confocal microscopy (Figure 2.8c).  Taken together, these data 
suggest that RAGE effectively delivers DNA into the cellular compartments in 
which TLR9 is activated and that expression of RAGE sensitizes cells to both 
synthetic and genomic nucleic acids in the extracellular environment.
RAGE-deficient mice have impaired inflammatory responses to DNA in the 
lung
 Given its ability to potentiate NF-κB activation in cultured cells, we sought 
to assess the role of RAGE in proinflammatory responses  to DNA in vivo.  RAGE 
is  highly expressed in mammalian lung epithelia140; we therefore hypothesized 
that RAGE might participate in immune recognition of DNA in the airways.  To 
address this possibility, we intranasally administered a low dose of CpG-B DNA 
to C57BL/6 wild-type or RAGE deficient (ager-/-) mice and evaluated 
inflammatory parameters in the lung at 24 hours after DNA exposure.  Wild type 
mice mounted a strong inflammatory response to CpG-B DNA, characterized by 
a significant increase in neutrophils  and the neutrophil granule product, 
myeloperoxidase, in bronchoalveolar lavage (BAL) fluid, and increased 
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expression of the neutrophil chemoattractant LIX (Figure 2.9a).  Strikingly, 
RAGE-deficient animals showed significantly lower neutrophil influx, with MPO 
and LIX levels indistinguishable from PBS-treated control animals  (Figure 2.9a). 
Histological analysis of lung tissue revealed marked perivascular and 
peribronchiolar leukocyte influx in wild type mice (Figure 2.9b, left panel) that 
was notably reduced in RAGE-deficient mice (Figure 2.9b, right panel).  Analysis 
of cytokines in the BAL fluid revealed significantly reduced production of IFN-γ, 
IL-6, TNFα, and IL-12p70 in RAGE-deficient animals as compared to the wild 
type (Figure 2.9c).  Of note, IL-1β and IFN-α, cytokines whose production is not 
directly activated by NF-κB, were also seen to be upregulated in wild type but not 
RAGE-deficient mice following CpG-B exposure, suggesting a broader role of 
RAGE in systemic inflammation. Taken together, these data indicate that RAGE 
expression plays an important role in the formation of an inflammatory response 
to immunostimulatory DNA in vivo, and particularly, in the lung.  
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Figure 2.9a-b RAGE mediates DNA-induced pulmonary inflammation in 
vivo.  C57BL/6 wild-type or RAGE-deficient mice were administered PBS with or 
without 5 µg CpG-B via the intranasal route and analyzed 24 hours later for signs 
of pulmonary inflammation. n=6 mice per group. (a) Neutrophil cell number (left 
panel), myeloperoxidase concentration (MPO, middle panel) and LIX 
concentration (right panel) were determined in bronchoalveolar lavage fluid. 
Data shown are representative of two separate experiments  (n=6 per group, per 
experiment) with similar results. Error bars  indicate standard error of the mean 
and p values assessed by the nonparametric Mann Whitney U test are noted. ns 
= differences are not significant. (b) Representative hematoxylin and eosin 
stained paraffin sections of lung tissue from wild-type and RAGE-deficient (ager 
-/-) mice 24 hours  after administration of 5 ug CpG-B.  Black arrowheads indicate 
areas of apparent leukocyte infiltration in the wild type tissue and comparable 
areas in the ager -/- tissue.   
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Figure 2.9a-b RAGE mediates DNA-induced pulmonary inflammation in 
vivo.
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are not significant.
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Discussion
The mechanisms of nucleic acid uptake from the extracellular milieu have long 
been a point of interest.  Because nucleic acid-recognizing TLRs are expressed 
in endosomal compartments, early work on these receptors assumed the 
likelihood of a cell surface “uptake” receptor39.  Discovery of such a receptor has 
been elusive, however, and the mechanism by which extracellular DNA gains 
access to intracellular receptors  remains largely unsolved.  A role in ligand 
uptake has been described for the TLR co-receptor protein CD14101,  integrins102 
and scavenger receptors103,104. However, few studies have shown direct 
biochemical evidence of DNA-receptor binding and an apparent functional 
redundancy complicates assigning an essential role to any single receptor. 
 Our work indicates that surface-expressed RAGE protein binds directly to 
nucleic acids and promotes their uptake into endosomal compartments, 
presumably facilitating their access to endosomal TLRs 3, 7, 8 and 9.  While 
RAGE does not appear to be essential for DNA to access TLR9 in cultured cells, 
its expression notably enhances the ability of TLR9-expressing cells to activate 
the transcription factor NF-κB.  The effect of RAGE is more dramatic in vivo, as 
mice lacking RAGE show a clear deficiency in their ability to mount a typical 
inflammatory response to TLR9-stimulatory DNA.  These findings shed new light 
on the role of RAGE in inflammation. 
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 It has  been suggested that direct signaling of RAGE upon ligation of 
glycated proteins, amyloid-beta fibrils, S100 proteins and HMGB1 serves to 
initiate and perpetuate inflammatory responses126,136,137,141.  Our work 
demonstrates a clear role for RAGE in uptake and intracellular trafficking of 
nucleic acid ligands; however, the occurrence or importance of a direct signal 
downstream of receptor ligation is, as yet, unclear.  
 Whether by simply modulating DNA uptake or by generating a regulatory 
signal, RAGE appears to be important in influencing the concentration threshold 
at which activation of inflammatory responses is achieved.  We gave mice a 
suboptimal dose of a TLR9 stimulatory ligand, which in the absence of RAGE, 
was not able to induce inflammation.  However, expression of RAGE at normal 
physiological levels permitted the animals  to mount a potent inflammatory 
response to low concentrations of DNA.  We speculate that such “thresholding” 
may serve to sensitize RAGE-expressing cells to the presence of DNA while 
allowing other cells to remain unactivated.  The multi-ligand nature of RAGE may 
also contribute to thresholding of responses.  It has been proposed that 
complexes containing multiple RAGE ligands and/or complexes capable of 
simultaneously ligating RAGE and other receptors  (such as DNA-HMGB1-
containing immune complexes seen in systemic lupus erythematosus) may 
provide a symphony of signals that allow the immune system to distinguish 
between distinct types of danger175.  Such synergy between multiple RAGE 
ligands may help to reconcile our observation of a direct RAGE:DNA interaction 
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with published data indicating that HMGB proteins, also RAGE ligands, are 
required for TLR activation by nucleic acids176.  
 The roles of co-receptors, such as HMGB1, and nucleic acid sequence in 
RAGE-mediated DNA responses is still somewhat unresolved.  While our 
previous work suggested that a DNA:HMGB1 complex was more effective at 
activating plasmacytoid dendritic cells than HMGB1 alone106, the binding studies 
presented here, which were carried out in the absence of HMGB1, indicate that 
HMGB1 is not essential for the RAGE-DNA binding event.  However, HMGB1 is 
commonly present in mammalian serum and induced during tissue damage; 
thus, possible synergy between DNA and HMGB1 in the initiation of inflammation 
remains to be elucidated.  With or without the help of co-receptors, specificity for 
distinct nucleic acid sequences or structures  is  a hallmark of many known nucleic 
acid sensors.  Under normal physiological conditions, an unmethylated CpG 
dinucleotide motif9 is required for activation of TLR9.  Such a CpG sequence has 
also been reported as necessary for DNA binding to RAGE128.  Our data, 
however, strongly suggest that the DNA-RAGE interaction occurs irrespective of 
nucleotide sequence. Co-crystalization of RAGE with bound DNA indicates that 
the binding is mediated entirely by interactions of the negatively charged 
phosphates of the DNA backbone with charged and hydrophilic residues at the 
RAGE:ligand binding interface. Additional binding studies using non-CpG 
oligonucleotides and base-free sugar-phosphate backbones, which also bound 
RAGE with no notable loss of affinity, further support a sequence-independent 
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binding modality. This lack of specificity seems to extend to RNA ligands, as both 
ssRNA oligonucleotides and base-free RNA backbones  interacted with RAGE in 
a manner similar to DNA.
 Charge-based binding is emerging as a generalized mechanism for 
interaction of RAGE with its  ligands. It has previously been demonstrated that 
glycated BSA, which is  highly acidic, may engage in electrostatic interactions 
with RAGE in a manner similar to that of dsDNA shown here.129  Additionally, 
NMR spectroscopic analysis  of calcium-bound S100b interaction with RAGE 
suggested that their interface resides adjacent to the area we designate “site 1” 
of the dsDNA binding surface111.  Truncation of the acidic C-terminal tail region of 
HMGB1 has also been shown to significantly diminish its association with 
RAGE177, suggesting that electrostatic interactions are key for any direct HMGB1 
binding. It thus appears that the large positively charged surface of the RAGE V-
C1 domains, of which only a portion is involved in dsDNA binding, may be able to 
engage distinct negatively-charged ligands through similar electrostatic 
attractions.  Interestingly, charge-based interaction has also been suggested as 
the mechanism of DNA binding to other cell surface receptors178,179 and may help 
to explain the apparent functional redundancy of receptors that interact with 
negatively charged ligands in the extracellular space.  
 While the interaction mechanisms described here are ostensibly 
applicable to any environment in which DNA and RAGE are present, 
physiological expression patterns of RAGE suggest that it may be particularly 
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important for inflammatory responses raised in the lungs. The predominant site of 
RAGE expression in adult mammals is in lung tissue150, where the receptor is 
highly expressed on alveolar epithelial cells140,180.  Several types of immune cells 
have also been described to express RAGE150-153,181,182, though whether such 
expression is constitutive or inducible is not well defined.  Various conditions can 
expose such cells to free DNA and RNA in the lung.  For example, acute 
infections such as pneumococcal pneumonia, which is  characterized by bacterial 
autolysis  and release of foreign DNA into the lung183, present a likely scenario in 
which nucleic acids would be accessible to a cell-surface receptor.  Chronic 
pathological conditions, such as  the accumulation of DNA-containing bacterial 
biofilms in cystic fibrosis160 and the deposition of nucleic-acid containing immune 
complexes in the interstitial space of lupus patients184, also expose lung cells  to 
free extracellular DNA and RNA.  Moreover, inflammation in the lung is often 
characterized by recruitment of neutrophils  and formation of neutrophil 
extracellular traps (NETS), which involves extrusion of the cell’s own DNA185. 
These and other situations  suggest that recognizing extracellular nucleic acids of 
foreign or host origin may serve a broad function in detecting infection and tissue 
damage in the lung. The surface receptor protein RAGE, through its ability to 
concentrate DNA and RNA on cells  and promote their uptake into specific 
receptor-containing intracellular compartments, may play a key role in regulating 
the initiation of immune responses to nucleic acids.
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Materials and Methods
Oligonucleotides
Oligonucleotide (ODN) sequences and sources are listed in Table 2.2. Base-free 
phosphodiester and phosphorothioate backbones were a kind gift from Dr. 
Herman Wagner (Technical University Munich, Germany). 
Cell Lines 
Cell lines in the HEK293, 293T and HeLa backgrounds were generated using 
retro- or lentiviral transduction with human RAGE C-terminally fused to 
fluorescent protein tags. cDNA encoding the human RAGE 404 amino acid 
transmembrane protein isoform (GenBank accession number AY755619) was 
amplified by PCR using upstream primer 
5’-AAAACTCGAGATGGCAGCCGGAACAG-3ʼ and downstream primer 5’-
AAAAAGATCTAGGCCCTCCAGTACTACTCTCG-3’.  RAGE cDNA and cDNA 
encoding CFP or YFP were sequentially subcloned into the murine moloney 
leukemia virus-based retroviral packaging vector pRP (Figure 2.10, produced by 
Brian Monks). To produce transducing retroviruses, 293T cells (220,000 per well 
in 96-well plates) were simultaneously transfected with pRP (100 ng) and 
plasmids encoding HIV gag-pol (100 ng) and VSV-G (10 ng) using TransIt 
reagent (Mirus Bio).  Culture supernatants containing retrovirus were added to 
pre-existing target cell lines of interest and RAGE-positive cell lines were 
selected based on resistance to puromycin.  Limiting dilution was used to  
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Table 2.2 Oligonucleotide sequences and sources.
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Figure 2.10  pRP retroviral transduction vector.
RAGE-fluorescent protein chimeras were cloned into the vector at the BglII 
restriction site.  
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produce clonal cell lines. 
 For the tetracycline-inducible RAGE cell line, cDNA encoding human RAGE 
and the fluorescent protein mCitrine or mCerulean were cloned into the 
pEN_TTmcs entry vector (Addgene 25755) and transferred to the pSLIK-hygro 
vector (Addgene 25737) by recombination (both plasmids were the gift of Dr. Iain 
Fraser and are commercially available through Addgene). pSLIK plasmids were 
delivered using a lentiviral transduction system186.  
Binding Studies
Recombinant protein production is described in Additional Detailed Methods. In-
vitro binding of biotinylated oligonucleotides to purified, his-tagged, human RAGE 
extracellular domain (V-C1-C2) was assayed using the AlphaScreen amplified 
luminescent proximity assay (Perkin Elmer)186.  Titrations of oligonucleotides 
were incubated with 40 nM RAGE-his in buffer (50 mM Tris-HCl pH 7.4, 100 mM 
NaCl, 1% ultrapure BSA, 0.01% Tween 20) at 22 ºC for 30 minutes, followed by 
addition of streptavidin-conjugated donor beads and nickel-chelate acceptor 
beads for 10 minutes or longer.  Fluorescence was analyzed with an Envision 
plate reader (Perkin Elmer).  For confocal imaging studies of DNA binding to the 
cell surface, HeLa cells expressing RAGE-CFP and Rab4a-YFP or only Rab4a-
YFP, were cultured on glass-bottom dishes (MatTek) overnight, then incubated 
with 1 µM  ODN 2336-AlexaFluor 647 at 37 ºC for 5 minutes, washed with 
medium, and imaged by confocal microscopy. For flow cytometry analysis of 
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DNA binding to RAGE-positive and RAGE-negative cells, 293T cells expressing 
tetracycline inducible RAGE-mCitrine were cultured overnight in medium with or 
without 10 µg/mL tetracycline, then incubated with 1 µM Alexa 647-labeled ODN 
2336 on ice for 30 minutes.  Cells were washed with PBS and analyzed on a BD 
LSR II instrument (Becton Dickinson) using BD FACS Diva (Becton Dickinson) 
and FlowJo software (Treestar, Inc.).  
DNA Uptake Studies
Uptake of DNA by RAGE-positive versus RAGE-negative cells was assessed 
using a tetracycline-inducible RAGE-mCitrine cell line.  Cells  in multiwell plates 
were cultured overnight in medium with or without 10 µg/mL tetracycline, then 
incubated with the indicated concentrations of AlexaFluor 647-labeled ODN 
2006, 2336 or transferrin for 30 minutes on ice or at 37 ºC.  Cells were washed 
with PBS and analyzed on a BD LSR II instrument (Becton Dickinson) using BD 
FACS Diva (Becton Dickinson) and FlowJo software (Treestar).  For confocal 
microscopy analysis of DNA uptake and trafficking, HeLa cells stably expressing 
RAGE-CFP and either Rab5a-RFP or Rab9a-YFP were cultured on glass-bottom 
dishes (MatTek) overnight.  Cells were “pulsed” with 500 nM Alexa 647-labeled 
ODN in medium for 5 minutes at 37 ºC, washed with PBS, and then incubated in 
medium for the indicated time periods prior to imaging.  For quantification of 
RAGE and DNA colocalization with early and late endosomes, total labeled 
endosomes were manually counted in 3-6 cell images.  Endosome spots 
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fluorescing in all three channels (endosomal marker, RAGE, ODN), were 
considered “triple-positive.” 
Confocal Microscopy
Live cells were seeded at 20,000 - 30,000 cells in 100 µL medium on glass-
bottom culture dishes (MatTek) and cultured overnight prior to treatment and 
imaging. Images shown represent a single z-plane though the approximate 
center of the cells  of interest. Images were obtained with Leica SP2 AOBS or 
SP5 SMD confocal microscopes. Sequential scanning was used to avoid cross 
excitation between fluorescence channels. 
Förster Resonance Energy Transfer (FRET) Measurements 
HEK293 cells  coexpressing RAGE-CFP and RAGE-YFP were brought into 
suspension and incubated in PBS with the indicated CpG ODN on ice for 20 
minutes. After further incubation at 37 ºC for 5 minutes, the cells were washed 
with ice-cold PBS and kept on ice until flow cytometry FRET analysis was 
performed as previously described187. RAGE-CFP or RAGE-YFP single 
transfectants were used as controls. Microscopy-based sensitized emission 
FRET was performed using a Leica SP5 SMD confocal microscope. HEK293 
cells were cultured on glass-bottom dishes  and incubated with 10 µg/mL 
doxycycline for 24 h to express  tetracycline-inducible RAGE-mCerulean and 
RAGE-mCitrine alone (as controls) or together. Cells  were then treated with 0.25 
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µM AlexaFluor 647-labeled ODN 2006 or 2336 for 15-30 minutes  at 37 ºC and 
imaged. FRET efficiency in areas of DNA:RAGE interaction was assessed by 
Leica TCS software, color coded as  indicated, and representative cells were 
graphed.
RAGE Crosslinking 
The amine-reactive crosslinking agent bis(sulfosuccinimidyl) suberate (Pierce) 
was prepared as a stock solution in water and diluted in PBS to working 
concentrations. Adherent HEK293 cells expressing human RAGE-YFP were 
detached from culture flasks and washed 3 times with PBS to remove amine-
containing serum components.   300,000 cells per sample were incubated in PBS 
with or without crosslinker for 30 minutes on ice.  Cells  were then gently pelleted 
by centrifugation, BS3-containing supernatant was removed, cells were lysed in 
Laemmli buffer (63 mM Tris-HCl, 10% glycerol, 2% sodium dodecyl sulfate, 
0.0025% bromophenol blue), and samples were analyzed by denaturing gel 
elctrophoresis  and immunoblotting with antibody directed against the YFP tag 
(anti-GFP mAb, Clontech).  Identical results  were obtained in similar experiments 
with cells expressing tetracycline-inducible RAGE labeled with a monomeric 
Citrine tag, indicating that the weak dimerization potential of YFP was not the 
sole driver of chimeric RAGE dimerization in these cell lines.
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Luciferase Reporter Assays
HEK293 cells stably expressing human TLRs 2 and 9, tetracycline-inducible 
human RAGE-mCerulean and a firefly luciferase gene under the control of the 
NF-κB inducible ELAM promoter were incubated overnight with 10 µg/mL 
doxycycline to induce RAGE expression, or left uninduced. Cells were stimulated 
as indicated for 8-16 hours and luciferase activity was assessed using SteadyGlo 
substrate (Promega) and an Envision multiwell plate reader (Perkin Elmer). 
HEK293 cells  stably expressing human TLR9 and tetracycline-inducible human 
RAGE-mCerulean were co-cultured with immortalized mouse C57BL6 
macrophages alone or with silica (Min-U-Sil 15, Western Reserve Chemical) for 6 
hours prior to luciferase analysis or confocal microscopy. 
Mice and In Vivo Studies
RAGE deficient (ager-/-) mice were produced by Taconic Artemis  Pharmaceuticals 
(Cologne, Germany). Experiments were approved by the MedImmune, LLC 
internal Institutional Animal Care and Use Committee (IACUC), protocol 
MI-09-007. Mice were anesthetized with isofluorane prior to intranasal inoculation 
of 5 µg of CpG-B ODN 1826 in a total volume of 50 µl of PBS. 24 hours after 
DNA administration, bronchoalveolar lavage fluid (BALF) was collected by 3 x 0.6 
ml washes with PBS/10mM EDTA/20mM HEPES, and lungs were harvested for 
histology. Lung tissue was inflated with 10% formalin prior to paraffin embedding, 
sectioning and staining with hematoxylin and eosin. Cytokines in BALF were 
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assessed by an MSD platform (MesoScale Diagnostics). IFNα (PBL Interferon 
Source), and LIX (R&D Systems) were measured by ELISA. Myeloperoxidase 
was quantified with a kit from Cell Sciences. Data shown are from one of two 
independent experiments with similar results. 
Structural Determination
Human RAGE V-C1 domain (residues 23-237) was expressed in bacteria and 
purified using metal-ion affinity, hydrophobic interaction, and size-exclusion 
chromatography (see Additional Detailed Methods). V-C1:DNA complexes were 
crystallized and the structures determined by molecular replacement with ideal 
dsDNA and the V-C1 domain structure as search models  111,129. Model building 
and refinement were carried out as detailed in Additional Detailed Methods and 
in Table 2.1. The structures and X-ray diffraction data were deposited at the 
RCSB protein data bank with accession numbers 3S58 and 3S59.
Statistical Analyses
Error bars in figures represent standard error of the mean for multiple samples, 
unless otherwise noted.  Data sets  were assessed for normality and significance 
of differences  (p value) in cell culture-based assays was evaluated using 
unpaired t-tests, with alpha defined as  0.05. Significance of differences in animal 
studies was evaluated using nonparametric Mann-Whitney U tests, with alpha 
defined as 0.05. U Tests  compared the untreated and DNA-treated group of the 
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same genotype, and the DNA-treated group of each genotype, as indicated. 
Prism software (GraphPad Software, Inc.) was used for all statistical analyses.
Additional Detailed Methods
Protein expression and purification
Protein for AlphaScreen binding studies: His-tagged human RAGE extracellular 
domain and deletion mutants containing the V domain (amino acids 1-121), V-C1 
domains (amino acids  1-258) or C1-C2 domains (amino acids 122-342) were 
amplified by PCR and cloned into a his-tag containing plasmid. For the C1-C2 
deletion mutant, the RAGE leader sequence was added to the constructs by 
overlapping extension PCR. To generate recombinant RAGE deletion mutant 
proteins, expression vectors were transfected into Freestyle 293F cells 
(Invitrogen) and his-tagged proteins were subsequently purified from the cell 
culture supernatants using a HisTrap column (GE Healthcare) and a DuoFlow 
FPLC system (BioRad). Proteins were eluted from the column in high salt buffer 
containing 500 mM sodium chloride and 25 mM imidazole, and dialyzed against 
PBS.
Protein for structural analysis: The V-C1 domain (Ala23 to Glu237) of human 
RAGE was cloned into a pET30a vector (EMD Biosciences) with a TEV cleavable 
N-terminal GB1 tag. Transformed BL21 (DE3) Codon Plus RIPL cells 
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(Stratagene) were grown at 37 °C until OD600 reached 1.2. Cells were then 
induced with 0.2 mM IPTG at 18 °C for 4 hours, harvested and resuspended in a 
buffer containing 100 mM NaCl, 5 mM imidazole and 20 mM Tris-HCl pH 8.0, 
supplemented with DNase- (Biomatik) and protease inhibitors (Roche Applied 
Science). Cells were lysed by sonication, and soluble protein was purified from 
cleared cell lysate by HisPrep IMAC column (GE Healthcare Bio-Sciences). Non-
specific DNA contaminants were removed by adding ammonium sulfate powder 
to the IMAC elution fractions to a final concentration of 3 M. The protein pellet 
was dissolved in a buffer containing 100 mM NaCl and 20 mM Tris-HCl, pH 8.0, 
before TEV protease cleavage of the expression tag. The RAGE V-C1 domain 
was further purified by a second IMAC column, followed by phenyl-Sepharose 
hydrophobic interaction chromatography and size exclusion chromatography.
Crystallization
DNA oligos were synthesized by Integrated DNA Technologies without a 5’-
phosphate. dsDNA with different sequences and lengths  were tested in co-
crystallization with the RAGE V-C1 domain. The two 22mer dsDNA oligos used in 
the current crystal structures were derived from vaccinia virus genomic repeat 
sequences (annealed from 5’-CCATGACTGTAGGAAACTCTAG-3’ and 5’-
GCTAGAGTTTCCTACAGTCATG-3’)  and CpG sequences (annealed from 5’-
CTGCAACGATGCTACGAACGTG-3’ and 
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5’-CACGTTCGTAGCATCGTTGCAG-3’).  Oligos were dissolved in a buffer 
containing 100 mM KCl, 5 mM DTT, 20 mM HEPES, pH 7.4. Complementary 
oligos were mixed at a 1:1 molar ratio, heated to 95 °C, and annealed by slow 
cooling to room temperature. Annealed dsDNAs were added to diluted protein 
solutions (1 mg/ml) and the protein-DNA complexes were concentrated with 
centrifugal concentrators (Millipore) to 10-20 mg/ml before setting up 
crystallization using the hanging drop vapor diffusion method. The RAGE V-
C1:DNA complex was crystallized with a well solution containing 12% PEG6000, 
and 0.1 M Tris-HCl, pH 7.4. A solution containing 12% PEG6000, 10% ethylene 
glycol, 10% glycol, and 0.1 M Tris-HCl, pH 7.4, was used as a cryoprotectant to 
freeze crystals in liquid nitrogen for data collection.
X-ray diffraction, structure determination and refinement
X-ray diffraction data were collected at GM/CA-CAT at the Advanced Photon 
Source (APS, Argonne, IL). Data were processed with the HKL200 program 
suite188 and XDS189. The RAGE V-C1-DNA structures were determined by 
molecular replacement with Phaser190 from the CCP4 program suite191. 
Previously reported RAGE structures111,129, and ideal dsDNAs from Coot192 or 
make_na server193 were used as the initial search models. Structure building and 
refinement were carried out with Coot and Phenix194. The final refined models 
show no gross structural changes for RAGE upon DNA binding. DNA base pair 
hydrogen bonding restraints were generated by the PDB to 3D restraints 
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server195 and employed during refinement. TLS parameters were generated by 
TLSMD server196 and Phenix194 and applied throughout the refinement, as well 
as twinned refinement protocols as suggested by the Xtriage program from 
Phenix194. Final structural models were validated by the Molprobity server197 and 
the RCSB ADIT validation server198. Electrostatic charge surfaces were 
calculated with Delphi software199 and displayed in Pymol (Delano Scientific LLC, 
San Carlos, CA).
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PREFACE to Chapter III
Figure 3.2 in this  chapter contains data excerpts from an article previously 
published in the journal Nature Immunology:
Tian J, Avalos  AM, Mao S-Y, Chen B, Senthil K, Wu H, Parroche P, Drabic S, 
Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Nawroth 
P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. 
Toll-like receptor 9-dependent activation by DNA-containing immune 
complexes is mediated by HMGB1 and RAGE. 2007. Nature Immunology 8 
(5):487-496. 
Data in Figure 3.2a were generated by E.L. using cells produced by C.M.S. 
Data in Figure 3.2b-c were generated by J.T. 
Chemical structure diagrams in Figure 3.3 were obtained from WikiMedia 
Commons (http://commons.wikimedia.org) and are not subject to copyright. 
All other figure components  in this  chapter represent unpublished data generated 
by C.M.S.
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CHAPTER III: Nucleic acid complexes are optimal RAGE ligands
Abstract
Complexation with specific antibodies and/or DNA- and RNA-binding proteins are 
common presentations of immunogenic nucleic acids in vivo.  We sought to 
address the ability of such complexes to interact with the receptor for advanced 
glycation end products (RAGE) and the functional implications of these 
interactions.  Here we show that DNA-containing immune complexes as well as 
DNA-HMGB1 complexes interact directly with RAGE.  Complexation of HMGB1 
with certain types of DNA modifies its binding to RAGE and its  ability to activate 
production of type-I interferon by plasmacytoid dendritic cells.  Additionally, 
nucleic acid-like posttranslational modification (poly-ADP ribosylation) of HMGB1 
may similarly influence the ability of this ligand to interact with RAGE.  These 
findings suggest that nucleic acid-containing multimolecular complexes may be a 
functionally significant format for RAGE ligands in vivo.  
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Introduction
Aside from experimental situations, extracellular nucleic acids are unlikely to 
persist in the body in “naked” forms.  A plethora of chromatin-associated 
structural proteins, polymerases and transcription factors associate with DNA and 
RNA in the intracellular environment.  Events that liberate self nucleic acids are 
likely to also release many of these associated proteins.  The same can be said 
of microbial nucleic acids  released by autolysis and other forms of bacterial death 
in tissues.  Thus, uncomplexed nucleic acids are likely to be truly rare in 
physiological contexts  of immunity.  While reductionist studies of purified nucleic 
acid ligands have lent important insights into the essential nature of DNA or RNA 
for activation of innate immune receptor proteins, a complete understanding of 
immune responses to nucleic acid-containing ligands requires consideration of 
the forms these ligands acquire in vivo.  
 The importance of nucleic-acid containing complexes in activating the 
immune system has become clear in studies of certain autoimmune diseases, 
particularly systemic lupus erythematosus (SLE) and Sjögren’s syndrome.  These 
diseases are characterized by the production of antibodies with specific 
paratopes for self components  such as chromatin, RNA and associated 
proteins200.  Once in the circulation, these so-called “autoantibodies” can bind to 
nucleic acid debris  associated with normal cell turnover, forming antibody-ligand 
aggregates known as immune complexes. In the absence of autoantibodies, 
97
such debris  is effectively degraded and disposed of by nucleases, proteases and 
the body’s scavenger functions.  However, the formation of immune complexes 
appears to promote recognition of self nucleic acids and inflammation201.  Many 
nucleic acid receptors preferentially activate signaling pathways that produce 
type-I interferons, and these cytokines play an important role in the pathogenesis 
of autoimmune diseases characterized by immune complexes202.  
 While the importance of antibody-based immune complexes in 
autoimmune diseases is quite clear, less attention has been paid to the 
complexing of nucleic acids by non-antibody proteins.  Recently, the mammalian 
antimicrobial peptide LL37 has been shown to associate with and complex 
extracellular DNA, and promote interferon production through activation of 
TLR9203.  Complexation of endogenous nucleic acids by LL37 appears to be a 
key factor in breaking normal immune tolerance to self DNA and promoting the 
skin pathology of the autoimmune disease psoriasis.  LL37 is  found in psoriatic 
skin lesions, and has been shown to convert non-stimulatory “naked” genomic 
DNA into a stimulatory ligand for plasmacytoid dendritic cells, the key type-I IFN 
producing cell type203.  Interestingly, LL37 associated with self DNA extruded 
from neutrophils  in extracellular traps (NETs) has been shown to also play a key 
role in interferon production in SLE204, suggesting that complexation of nucleic 
acids with this antimicrobial peptide can cause similar effects as  antibody-nucleic 
acid complexes.   
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 Somewhat more famous  than LL37, another intracellular protein that has 
gained recognition as an extracellular effector molecule is HMGB1.  This small 30 
kDa protein was identified in studies of calf thymus chromatin proteins  in the 
1970s, as one of a “high mobilility group” (HMG) that moved rapidly in gel 
electrophoresis205.  A subset of these  proteins are characterized by one or more 
DNA-binding “box” domains, and are thus  termed HMGB.  HMGB1, the most 
studied of the mammalian HMG proteins, is a non-histone structural protein that 
binds to chromatin in the nucleus to facilitate DNA bending and transcription 
factor binding206.  However, under conditions of cell stress or cell death, HMGB1 
can be released into the extracellular environment, where it serves as  a potent 
proinflammatory cytokine207,208.  Many of the proinflammatory effects  of HMGB1 
have been traced to its  interaction with RAGE on the cell surface209.  Thus, 
HMGB1 is both a RAGE binding protein and a DNA binding protein, as well as an 
inflammatory mediator.  This combination of attributes suggests that association 
of HMGB1 and DNA may affect RAGE in a synergistic manner.   
 Given the importance of nucleic acid complexes in the initiation of 
inflammation and the perpetuation of autoimmunity, we investigated the ability of 
RAGE to interact with nucleic-acid containing complexes.  
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Results
DNA-containing immune complexes interact with RAGE
Because naked nucleic acid ligands can effectively bind to RAGE in-vitro (see 
Chapter II), we sought to assess the relative binding of DNA-containing immune 
complexes to this receptor.  Synthetic immune complexes can be generated by 
mixing immunogens with specific antibodies in vitro.  We digested bacterial 
plasmid DNA with a multi-cutting restriction enzyme and incubated the fragments 
with a DNA-specific monoclonal antibody to generate dsDNA immune 
complexes.  Cut DNA incubated with anti-dsDNA antibody showed retarded 
migration in agarose gel electrophoresis, consistent with immune complex 
formation (Figure 3.1a).  Complexes generated in this manner were tested for 
their ability to bind directly to purified human RAGE extracellular domain in a 
physiological buffer solution.  Complexes were titrated over a range to give DNA 
concentrations roughly equivalent to that of CpG-A and CpG-B oligonucleotide 
controls (i.e., CpG oligos  were used at a starting concentration of 200 nM, 
roughly equivalent to 2 µg, the amount of DNA used in each complex).  Binding 
of immune complexes closely mimicked that of CpG-A DNA, with affinity in the 
low nanomolar range (Figure 3.1b). The CpG-A oligonucleotide is thought to 
aggregate into DNA-only complexes by virtue of G-tetrad formation between 
molecules.  The fact that both this DNA-only complex and the DNA-antibody 
complex showed similar binding signal, while the unimolecular CpG-B bound less
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Figure 3.1  DNA:antibody complexes bind to RAGE. 
(a) Characterization of DNA:antibody complexes by agarose gel electrophoresis. 
Electrophoretic mobility of complexes made from the indicated concentrations of 
cut plasmid DNA and anti-DNA monoclonal antibody were compared to plasmid 
DNA alone.  Retardation of DNA complexed to antibody is seen as upward 
smearing of bands. (b) The ability of DNA:antibody complexes (open blue circles) 
to bind to 10 nM purified, his-tagged human RAGE extracellular region (V-C1-C2) 
was assessed by AlphaScreen binding assay. CpG oligonucleotides and antibody 
alone served, respectively, as positive and negative RAGE binding controls.  
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favorably, suggests that complexes interact preferentially with RAGE in this 
binding assay.  
Complexes of HMGB1 and DNA are optimal RAGE ligands
Both HMGB1 and DNA have been reported to be direct RAGE ligands.  However, 
because HMGB1 is  a DNA binding protein, it is likely that these two ligands 
frequently exist as a complex in the extracellular environment.  We first sought to 
visualize the relationship of an HMGB1:DNA complex with RAGE.  In confocal 
microscopy studies, a complex of fluorescent CpG-A with HMGB1 was seen to 
associate with fluorescently-tagged RAGE on the cell surface (Figure 3.2a, left 
panel).  As  early as 10 minutes after addition, the complex and RAGE could be 
seen to colocalize in intracellular compartments resembling endosomes.  By 60 
minutes after addition, nearly all RAGE had been internalized from the cell 
surface and localized with HMGB1:DNA complexes within the cell (Figure 3.2a, 
middle panel).  To confirm that these compartments  were endosomes, we 
assessed the colocalization of fluorescently-tagged RAGE with fluorescently-
labeled transferrin after a 60-minute incubation.  Transferrin in complex with its 
specific receptor is known to enter early endosomes, where it releases its cargo 
of iron ions prior to transfer to recycling endosomes and return of the transferrin 
receptor complex to the cell surface37.  Many RAGE-containing compartments 
were transferrin-positive after 60 minutes of incubation (Figure 3.2a, right panel) 
suggesting that RAGE-associated uptake of HMGB1:DNA complexes occurs via   
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Figure 3.2  HMGB1:DNA complexes interact with RAGE and induce type-I 
interferon. 
(a) HEK293 cells expressing RAGE protein tagged with YFP were stimulated with 
fluorescently-labeled CpG-A oligonucleotide or fluorescently-labeled transferrin 
for the indicated times and imaged by confocal microscopy. Cell nuclei are 
stained with Hoechst dye (blue). (b) Binding to immobilized RAGE of HMGB1 
alone or complexed with CpG-A or CpG-B oligonucleotides was assessed in a 
plate-based binding assay. (c) Murine plasmacytoid dendritic cells were 
stimulated with HMGB1 or S100b alone, or with these ligands pre-incubated with 
CpG-A.  Interferon-α in culture supernatants after 24 hours of stimulation was 
measured by ELISA.  
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an endosomal route, similar to that observed for DNA alone (see Chapter II). 
 Because both DNA alone and DNA complexed with HMGB1 seem to 
interact in a similar manner with RAGE on cells, we sought to identify differences 
in ligand:receptor interactions at the molecular level.  We assessed the relative 
affinity of RAGE for HMGB1 alone versus DNA-complexed HMGB1 with a plate-
based binding assay.  A CpG-A:HMGB1 complex bound RAGE at a 
concentration more than 100 times lower than HMGB1 alone, or HMGB1 
complexed to CpG-B oligonucleotide (Figure 3.2b).  The large difference in 
signal between HMGB1 complexes containing aggregated CpG-A versus short, 
unimolecular CpG-B suggests that increased binding is not due to mere synergy 
between two RAGE ligands  (HMGB1 and DNA), but rather to attainment of a 
large complex structure.  
 To evaluate this possibility on a functional level, we stimulated murine 
plasmacytoid dendritic cells (pDC) with HMGB1 or another RAGE ligand, S100b, 
either alone or combined with CpG-A.  HMGB1 and S100b alone induced little 
interferon production by pDC in culture (Figure 3.2c).  Complexation of HMGB1 
with CpG-A, however, stimulated cells to produce IFN-α in a dose-dependent 
manner (Figure 3.2c).  S100b is not thought to bind to DNA and is unlikely to 
form complexes.  In keeping with this, a mixture of S100b and CpG-A was unable 
to induce strong IFN-a production from cultured pDC (Figure 3.2c).  Taken 
together, these data suggest that increased binding to RAGE and downstream 
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cytokine production are preferentially induced not just by combinations of RAGE 
ligands, but by the multimolecular complex structures that they form.  
Parylation of HMGB1 may contribute to RAGE binding
In addition to complexing with DNA, a post-translational modification, poly-ADP 
ribosylation (“parylation”), on HMGB1 may also enhance its interaction with 
RAGE.  Poly ADP-ribose (PAR) is a polymer of ADP-ribose moieties  derived from 
nicotine-adenine dinucleotide (NAD), and is covalently added to multiple sites on 
HMGB1 by poly ADP-ribose polymerases (PARP family members) in the cell 
nucleus210,211.  Parylation of HMGB1 facilitates its dissociation from chromatin 
and subsequent passive diffusion out of the nucleus211.  Once in the cytosol, 
HMGB1 can be released from the cell upon cell death or, in the case of 
monocytes and macrophages, through an active secretion process212-215.  NAD 
monomers have a chemical structure similar to that of an RNA adenine 
dinucleotide (Figure 3.3a), and thus, PAR is  structurally similar to polyadenosine 
RNA.  Because RNA binds directly to RAGE (see Chapter II), we hypothesized 
that PAR might also be a RAGE ligand.  We tested the ability of RAGE to bind to 
isolated PAR polymer using several variations of a plate-based binding assay. 
PAR and the RAGE extracellular domain showed detectable binding to each 
other, regardless of which of the two binding partners was immobilized on the 
plate (Figure 3.3b).  Activated PARP parylates itself as well as other proteins; 
RAGE also bound to immobilized parylated PARP (Figure 3.3b).  Taken together, 
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Figure 3.3  PAR is a RAGE ligand. 
(a) Chemical structures of poly-ADP ribose (PAR), nicotine adenine dinucleotide 
(NAD) and an adenosine RNA dinucleotide. (b) Cartoon representations  of plate-
based binding assays (top) and signal representing relative RAGE:PAR binding 
(bottom).  Background absorbance readings of negative controls = ~0.1. 
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these data suggest that RAGE is able to interact with parylated protein by virtue 
of direct binding to PAR adducts. Hence, parylation of HMGB1 might serve to 
increase its interaction with RAGE in a manner similar to complexation with DNA. 
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Discussion
The results presented here provide initial evidence that multimolecular 
complexes containing nucleic acids  or similar molecules such as PAR are optimal 
RAGE ligands.  Important future directions  for this work include directly 
evaluating the ability of parylated HMGB1 to interact with RAGE, and the 
outcome of this interaction in vivo.  Because glycohydrolases  that remove PAR 
moieties exist in the cytosol216, it is not yet clear whether HMGB1 is  de-parylated 
before its release from cells, or if parylation could play a role in inflammatory 
activation by extracellular HMGB1.  Parylated or not, there is strong evidence 
that HMGB1 is a component of naturally-occurring immune complexes, including 
those circulating in the serum of SLE patients217,218. Hence, the effects seen here 
for DNA-antibody complexes and DNA-HMGB1 complexes are likely to be 
similar, and perhaps further enhanced, when these components come together in 
vivo.   
 RAGE is expressed on many cell types, and exposure to particular ligands 
may vary depending on the tissue in which RAGE is  expressed.  Binding of 
individual ligands to RAGE has been shown primarily to initiate signaling 
pathways that result in activation of NF-κB.  While NF-κB-induced cytokines 
certainly play a role in autoimmunity219, type-I interferon has emerged as a key 
“signature” of nucleic acid recognition in several autoimmune syndromes220.  As 
shown here, single RAGE ligands like HMGB1 and S100 alone may not be 
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sufficient to induce interferon production, but complexation of HMGB1 can attain 
this  activation threshold.  Type-I IFN production by pDC, presumably through 
TLR9, is  preferentially activated by nucleic acids like CpG-A that adopt complex 
structures221. The data in this chapter provide preliminary evidence that 
multimolecular complexes of RAGE ligands may also activate this pathway, and 
suggest that receptor “clustering” may be a key event for IFN activation.  Given 
the large amount of evidence that RAGE preferentially activates NF-κB upon 
receptor ligation (see Chapter I), type-I IFN activation may be a smaller role that 
RAGE plays specifically after binding nucleic acid-containing ligands. 
Nevertheless, because type-I IFNs enhance their own production via feedback 
loops, small increases in IFN activation may translate into large differences in 
autoimmune pathology and thus, RAGE:ligand interactions may be a contributing 
factor in the cytokine balance of autoimmune diseases.     
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Materials and Methods
Studies of DNA immune complexes  
To generate immune complexes, plasmid pcDNA3 (Invitrogen) was digested with 
the restriction enzyme DpnI (Fermentas) to generate double-stranded DNA 
fragments. The indicated dilutions of monoclonal anti-dsDNA (MAB030, 
Chemicon) were mixed with 2 µg of cut DNA in PBS and incubated for 
approximately 1 hour at 4 ºC.  Preparations were used immediately or frozen at 
-20 ºC until use. Samples (containing 2 µg of DNA per well) were 
electrophoresed on a 1% agarose gel containing trace amounts of ethidium 
bromide, in Tris-borate-EDTA electrophoresis buffer, and the gel was imaged 
using a Gel Dock XR System with Quantity One software (BioRad).  
 For the AlphaScreen binding assay, the indicated dilutions of immune 
complexes were incubated with 10 nM his-tagged human RAGE extracellular 
domain (V-C1-C2) and 1 µg/mL biotinylated anti-mouse IgG monoclonal antibody 
in assay buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% ultrapure BSA, 0.01% 
Tween 20) for 30 minutes at room temperature.  Biotinylated CpG-A (ODN 2216, 
Integrated DNA Technologies) and CpG-B (ODN 2006 with a phosphodiester 
backbone, Integrated DNA Technologies) at the indicated concentrations were 
incubated with 10 nM RAGE-his in the same way.  Streptavidin-conjugated 
AlphaScreen donor beads and nickel chelate acceptor beads (Perkin Elmer) 
were added to the reaction and incubated for an additional 20 minutes at room 
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temperature.  Induced chemiluminescent signal was  measured with an EnVision 
plate reader and associated software (Perkin Elmer).
Studies of HMGB1:DNA complexes
Confocal microscopy:  HEK293 cells  were retrovirally transduced with an 
expression vector encoding full-length human RAGE with a YFP tag fused to the 
C terminus  (cytoplasmic domain).  HEK cells stably expressing RAGE-YFP were 
seeded onto glass bottom tissue culture dishes (MatTek) and cultured for 16 
hours in growth medium (DMEM, 10% FBS, 10 µg/ml ciprofloxacin). Cells were 
treated with Alexa647-conjugated human transferrin (Invitrogen) or a complex of 
HMGB1 (calf thymus derived, 3 g/ml; gift from MedImmune) and Bodipy 630/650 
conjugated CpG-A  (ODN 2216, 1 µM; Eurofins MWG Operon) for the indicated 
time periods. Nuclei were stained with Hoechst 33342 dye 5 minutes before the 
cells were imaged. After three washes in prewarmed growth medium, the cells 
were analyzed with a Leica TCS SP2 AOBS laser scanning confocal microscope. 
Sequential scanning was performed to ascertain separation of fluorescence 
emission with only one laser and the respective photomultiplier tubes active per 
scan.
 Binding assay: Recombinant Fc-tagged human RAGE extracellular 
domain was coated onto 96-well plates. HMGB1 alone or complexed with CpG-A 
(ODN 2216, Invivogen) or CpG-B (ODN 2006, Invivogen) was added and binding 
was detected by biotin-labeled monoclonal antibody to HMGB1.  
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 In vitro pDC stimulation: pDC were isolated from murine bone marrow 
cells (> 60% pure) using a plasmacytoid dendritic cell isolation kit (Miltenyi 
Biotec) and plated in 96-well plates at a density of 2.5 x 104 cells  per well.  Cells 
were stimulated for 24 hours with the indicated concentrations of ligands 
(HMGB1, produced internally at MedImmune; S100b, Calbiochem) alone, or pre-
complexed with CpG-A (ODN 2216, Invivogen). IFN-α in cell culture supernatant 
was measured by ELISA (R&D Systems).  
RAGE binding to PAR and parylated protein 
Plate-based binding assay: 96-well high protein binding plates (Maxisorp, Nunc) 
were coated with PBS containing either 0.6 µM his-tagged RAGE extracellular 
domain (gift from MedImmune) or 2 µg/mL anti-PAR monoclonal antibody 
(Trevigen) at 4 ºC overnight.  Wells were washed and then blocked with PBS 
containing 0.01% Tween 20 and 3% bovine serum albumin at room temperature 
for 1.5 hours.  PAR polymer (10 ng/uL, Trevigen) or parylated PARP protein (200 
nM) in blocking buffer were added for 2 hours at room temperature.  After 
washing, bound PAR or parylated PARP as detected by addition of anti-PAR 
polyclonal antibody (1:4000 dilution, Trevigen) followed by HRP-conjugated anti-
rabbit secondary antibody (BioRad) or 0.6 µM hRAGE-his followed by nickel-
HRP (BioRad).  Secondary antibodies alone and/or non-binding “ligands” plus 
secondary antibodies were used as negative controls. 
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Chapter IV: Discussion
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The panorama of nucleic acid sensing
Proper sensing of the location and origin of nucleic acids is  an essential process 
in maintaining structural homeostasis and in defending mammalian organisms 
from microbial and parasitic pathogens.  Nucleic acid-sensing receptor proteins 
are situated in specific locales, i.e., the extracellular face of cell membranes and 
the lumen of intracellular compartments, where the presence of DNA or RNA is 
indicative of cell damage or infection.  The origin of nucleic acids in these 
locations, and even more importantly, in the cytosol, is  further determined by their 
biochemical nature; for example, presence of unmethylated CpG dinucleotide 
motifs in DNA indicate bacterial or viral origin, while presence of a 5‘ triphosphate 
on RNA indicates that it was produced by a virus, not the mammalian cell.  The 
combination of “location” and “origin” information provides a code that allows the 
body to distinguish a true threat to its integrity, requiring immune and repair 
responses, from a minor disturbance that requires only “clean up” of misplaced 
nucleic acids.  Hence, proper interpretation of the location-origin code is  vital for 
efficiently controlled responses to nucleic acids.  Perhaps for this reason, an 
ever-increasing team of proteins intervene in various aspects of nucleic acid 
sensing and discrimination.  
 This  “team” can be divided into three conceptual divisions: access control, 
facilitation, and response.  “Access control” includes nucleases that simply 
eliminate DNA and RNA that they encounter, to prevent access of these 
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molecules to the “response” division.  “Facilitator” proteins are receptors like 
RAGE, and nucleic acid-complexing agents like HMGB1 and LL37 that help to 
protect nucleic acids  from nucleases and/or promote their uptake.  Combinations 
of access control and facilitation influence the relative ability of nucleic acids to 
interact with the “response” division, true sensor proteins that check for 
“passwords” in the biochemical structure of the nucleic acid and activate signals.  
RAGE, nucleic acids, and inflammasomes
The preceding chapters  have considered the manner in which a facilitator 
protein, RAGE, interacts with nucleic acids in the extracellular environment and 
influences the activation of endosomal TLRs (response mediators).  Despite this 
empirical focus, the data presented here also shed light on potential roles  for 
RAGE in activation of immune sensors other than TLRs.  Both Chapters  II and III 
highlight ways in which “bulky” ligands, either multimers of CpG-A or complexes 
of DNA and proteins, interact preferentially with RAGE.  Another bulky RAGE 
ligand, amyloid-β fibrils, has been shown to activate the NOD-like receptor family, 
pyrin domain containing 3 (NLRP3) inflammasome, an IL-1β processing 
complex222.  The essential activating stimulus for NLRP3 is still somewhat cryptic 
and several hypotheses have been put forward223.  Fibrillar amyloid-β seems to 
induce inflammasome activation by disrupting the integrity of endolysosomes222, 
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and the same mechanism of action has been shown for other activators, such as 
large crystalline structures224.  There is, then, reason to speculate that large 
complexes taken up by RAGE into the endolysosomal network may also be able 
to “burst” these compartments in a manner similar to that shown for amyloid-β, 
leading to inflammasome activation.  This might account for the finding that CpG 
DNA administered into the murine lung could induce IL-1β secretion into the 
airways in a RAGE-dependent manner (see Chapter II).  While the CpG-B 
oligonucleotide used in those experiments does not form bulky structures on its 
own, complexation of the oligo with proteins  in vivo (refer to Chapter III) might 
serve to create an inflammasome-activating stimulus.  The endolysosomal 
rupture hypothesis is closely associated with another proposed mechanism of 
NLRP3 activation by reactive oxygen species (ROS)223,225.  Although this thesis 
work did not find evidence of direct signaling of RAGE upon nucleic acid ligation, 
interaction of RAGE with its other ligands has been reported to induce 
ROS139,141,142,226.  Hence, there are two potential mechanisms by which bulky 
and/or nucleic-acid containing RAGE ligand complexes may activate IL-1 via the 
NLRP3 inflammasome.  It is furthermore interesting to note that both RAGE227 
and NLRP3228 have been implicated in the pathology of atherosclerosis.  RAGE 
activity has been proposed to explain the link between diabetes  (in which AGEs 
are increased in the bloodstream) and vascular disease (which is exacerbated by 
inflammation)229,230.  The ability of nucleic-acid containing RAGE ligands to exert 
effects similar to those of AGEs may thus contribute to the documented 
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connection between atherosclerosis and the immune complex disorder 
SLE231-234.   
 Another IL-1-activating inflammasome complex is formed by the cytosolic 
DNA sensor absent in melanoma 2 (AIM2)87,235.  AIM2 has been reported to 
interact with several kinds of double-stranded synthetic and pathogen-derived 
DNA87,236-238.  While the evidence presented here shows that RAGE facilitates 
uptake of DNA into endosomes (see Chapter II) not cytosol, the endolysosomal 
rupture model suggests a mechanism by which nucleic acid RAGE ligands in 
intracellular compartments could also gain access  to cytosolic AIM2.  Hence, 
disruption of endolysosome integrity may be capable of inducing an IL-1 
response via two distinct inflammasome receptor complexes.  As IL-1β is one of 
the most potent inflammatory cytokines and an important mediator of both 
beneficial and pathological immune responses, this  potential role for RAGE and 
nucleic acids in inflammasome activation warrants further experimental 
interrogation. 
DNA, PARP, HMGB1 and RAGE: regulatory integration?
To again recall John Muir’s words (see Chapter I), in attempting to “pick out” the 
ways in which HMGB1 might interact with RAGE, we found that, though perhaps 
not connected to “everything in the universe,” it was  certainly connected to many 
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processes in the nucleus, cytosol and extracellular environment.  As discussed in 
Chapter III, HMGB1 both binds DNA and becomes poly-ADP ribosylated in the 
nucleus.  Upon recognizing that poly-ADP ribose (PAR) is  structurally similar to 
RNA, we became interested in its ability to interact with RAGE and found that it 
could do so (see Chapter III).  This opens  the possibility that HMGB1 may ligate 
RAGE via PAR and/or bound DNA.  It is  worth recalling that HMGB1 consists of 
two DNA-binding box domains (A-box and B-box), in addition to a 30 amino acid 
“tail” domain consisting solely of aspartic acid and glutamic acid residues.  Direct 
HMGB1 binding to RAGE has been suggested to be mediated by this acidic 
tail177, and the tail also appears to fold back on the box regions to block DNA 
binding sites239. It would therefore appear that acidic, negatively-charged 
molecules interact both with the box regions of HMGB1 and with the ligand 
binding region of RAGE (see Chapter II).  It is  thus conceivable that bound DNA 
could serve as a “bridge” between HMGB1 and RAGE, mediating indirect 
binding.  Under other circumstances, parylation on HMGB1 might play a similar 
role in mediating indirect binding, while a direct interaction between the HMGB1 
tail and RAGE could also occur.  This  variety of likely binding modalities  suggests 
that the nature of the RAGE:HMGB1 interaction could vary depending on the 
manner in which HMGB1 is  released from cells  (parylated or not), the absence 
vs. presence of extracellular DNA, and the relative concentration of these factors 
in the environment.  By this  logic, direct ligation of RAGE by individual ligands 
(HMGB1 alone, nucleic acid alone, PAR alone) may promote different receptor 
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function than ligation of RAGE by a multimolecular complex of interacting ligands 
(refer to Chapter III, Discussion).
 Beyond basic ligand-receptor considerations, cell stress  responses 
relating to HMGB1 and parylation may also be tied to RAGE (Figure 4.1).  As 
noted above, RAGE signaling appears to induce the generation of reactive 
oxygen species (ROS).  ROS production during inflammation and cell stress is 
linked to DNA damage240, and damaged chromatin is the activating trigger for 
poly-ADP ribose polymerases (PARP)241.  PARP activation leads  to HMGB1 
parylation and release from the cell211, which can then feed back on RAGE, to 
promote further inflammatory signaling.  Additionally, extracellular signal-
regulated kinases (ERK1/2), which are activated by RAGE, can activate PARP 
even in the absence of DNA damage242.  Hence, RAGE signaling may upregulate 
the release of its own ligands (HMGB1 and other parylated proteins) from 
intracellular stores.  Furthermore, PARP has been shown to directly co-activate 
transcription by NF-κB243,244, the predominant transcription factor induced by 
RAGE (see Chapter I). Both the presence of PARP243 and its  acetylation by 
nuclear cofactors244 were shown to be important for optimal NF-κB activation. 
This  suggests that PARP regulation under cell stress conditions could modulate 
activation of NF-κB and its  role in the RAGE feedback loop (refer to 134). Taken 
together, the known connections between PARP, HMGB1, DNA, RAGE, kinases, 
and transcription factors suggest a complex regulatory network in which all of 
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Figure 4.1  Model of the hypothetical interregulatory network formed by 
RAGE, HMGB1 and PARP.  
For narration of the model and for explanation of abbreviations, please refer to 
the text and the List of Abbreviations.
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these players  contribute to modulation of cell stress  responses and inflammation. 
Clearly defining the biology of these interactions may help to elucidate 
demonstrated connections between DNA damage, chronic inflammation, and 
cancer, as well as develop effective therapeutics that intervene in this network.
RAGE: a multifaceted modulator
The research presented here has focused on the manner in which RAGE 
interacts with nucleic acid-containing ligands, and the potential downstream 
consequences of these interactions on cell biology, inflammation and 
homeostasis.  However, a survey of the RAGE literature indicates many distinct 
functions for RAGE, beyond that of a nucleic-acid receptor.  While the interaction 
of RAGE with its other known ligands was discussed in Chapter I, several other 
functional roles for RAGE are worth acknowledging here:
1. RAGE is important in development of the nervous system.  HMGB1 was 
initially identified as a RAGE ligand important in neurite outgrowth, the process 
by which developing neurons in the central nervous system begin to form 
axons and dendrites110.  S100 proteins may induce similar effects in 
developing neurons and have been tied to growth of nervous system 
tumors245.  RAGE also appears to aid in regeneration of damaged peripheral 
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nerves246, thus supporting a role for this  receptor in multiple aspects  of 
neuronal growth. However, RAGE-deficient mice show no major 
developmental defects, neural or otherwise (refer to 247), indicating that these 
roles in nervous system development are either redundant, or consist of subtle 
modulatory effects.        
2. RAGE is involved in cell adherence and spreading. Expression of RAGE in 
HEK293 cells has been shown to increase the ability of these cells to adhere 
and spread on collagen IV-coated glass.  Because collagen IV is  a component 
of basement membranes248 and the alveolar epithelial type-I cells that form 
alveolae highly express RAGE140,249, this  receptor may play an important role 
in the formation of alveolae during lung development (refer to 149) or tissue 
repair.  Interaction of cells with extracellular matrix is by no means limited to 
lung epithelia, and thus, RAGE may promote adherence in multiple cell types 
that express it.  
3. RAGE induces cytoskeletal rearrangement.  Cell growth, adherence and 
spreading mentioned in points 1 and 2 all require remodeling of the actin 
cytoskeleton.  It is perhaps not surprising, then, that RAGE has been shown to 
associate with various proteins involved in cytoskeletal dynamics119,137. 
Demonstrated defects  in formation of actin rings and podosomes in RAGE-
deficient bone marrow precursor cells are a striking example, and these 
defects  prevent proper development of bone-resorptive osteoclast cells.250  As 
signaling and vesicular trafficking in the cytoplasm are all tied to the structural 
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framework of the cell, connections between cytoskeletal changes, RAGE 
ligand uptake, and RAGE signaling are likely to be an integrated and dynamic 
process.   
4. RAGE interacts with integrins.  RAGE has been reported to be a direct 
counter-receptor for the β2 integrin Mac-1 (CD11b)127, and a key factor in 
leukocyte recruitment251.  While interactions seem most likely to occur between 
Mac-1 on macrophages and RAGE on endothelia and epithelia, same-cell 
interactions of RAGE with αVβ3 integrins  have also been suggested250.  It is 
interesting to note that the two different RAGE dimer orientations  described in 
Chapter II could account for these same-cell and inter-cell interaction 
modalities. 
How might one reconcile the multiplicity of distinct RAGE functions with its role 
as a nucleic acid receptor?  What is  the advantage of having a single receptor 
interact with so many distinct ligands, and initiate multiple, distinct (and oft 
converging) signaling pathways?  
 I propose that RAGE serves  as a clearinghouse for signal integration. 
Because of its broad ability to ligate negatively-charged molecules, it is  an ideal 
integrator of multiple signals in a number of distinct tissue environments, 
including brain, lung and vasculature.  The variety of roles attributed to RAGE 
may have more to do with the specializations of the cells by which it is 
expressed, than differences in receptor function itself.  That is to say, in the 
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presence of growth signals, a neuron should grow.  When in contact with the 
extracellular matrix, an epithelial or endothelial cell should adhere and spread. 
And in the presence of danger signals, an immune cell should respond. In the 
context of inflammation, RAGE seems to provide information about the type of 
threat that is  perturbing homeostasis.  Because of its  location on the plasma 
membrane, RAGE senses that danger exists in the extracellular space. 
Detection of DNA in this environment indicates that self cells have been 
damaged or bacteria are present.  Complexes of DNA with DAMPs like HMGB1 
and LL37 indicate that a cellular response has  already been initiated, thus 
releasing these molecules.  The cellular response that led to formation of ligand 
complexes may be due to viral infection, and hence anti-viral interferon 
production is warranted. Production of cytokines and chemokines by “first 
responder” cells serves, in part, to recruit additional leukocytes and lymphocytes 
to the affected area.  Thus, the ability to promote cytoskeletal rearrangement 
necessary for motility, as well as the ability of RAGE to simultaneously sense 
molecular patterns  and interact with integrins on migrating cells, provides an 
efficient means of promoting response amplification. Interestingly, response 
downregulation is also built into RAGE function.  Secretion of soluble RAGE 
(sRAGE) or cleavage of surface-expressed RAGE releases a decoy receptor into 
the extracellular milieu that can block the multiple effects of the membrane-bound 
receptor252.  Upregulated release of sRAGE by epithelial cells upon cytokine 
stimulation has been shown in culture119, and changes in sRAGE levels are 
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considered biomarkers in certain human diseases.  Low levels  of circulating 
sRAGE correlate with pathology in chronic inflammatory diseases like 
rheumatoid arthritis and atherosclerosis252, suggesting that lack of blocking by 
sRAGE leads to greater inflammation.  Paradoxically, high sRAGE levels have 
been found in SLE252 and may represent an active, but inadequate, attempt to 
downregulate nucleic acid recognition pathways.  Thus, RAGE may serve 
alternately as an amplifier and dampener of inflammatory responses, depending 
on the relative expression of its isoforms. 
 Perhaps the most important attribute for RAGE as a signal integrator is its 
regulability.  Low constitutive expression in endothelia, epithelia and immune 
cells  likely serves to keep RAGE among the very earliest sensors of 
perturbations in the environment.  One could think of this  as the “patrol officer” 
function of RAGE.  Yet, RAGE may be most effective when it becomes 
upregulated in areas of ligand concentration.  This could be considered the “riot 
police” function; large amounts of receptor are deployed to handle an increased 
disturbance in the environment.  Just as having a high number of police on the 
streets all the time is a waste of resources and may lead to excessive martialism, 
high expression of a ligand-promiscuous, proinflammatory receptor is not 
something that would be of benefit under normal conditions.  But in the same 
way riot police can help return a city to normalcy, so can expression of a master 
integrator of inflammatory signals, when the time is right.  
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 This  combination of regulability, site-specific expression, and promiscuity 
in both ligand binding and initiation of signaling cascades positions RAGE as  an 
“ombudsman” molecule in cellular responses.  It can sense the presence of key 
stimuli, influence their access to intracellular receptors, and either amplify or 
block signal generation, as the circumstances warrant.  Although it is central in 
these processes, the role of RAGE is modulatory and often subtle, hence a lack 
of clear insufficiencies  in RAGE knockout animals, and seemingly paradoxical 
disease phenotypes in both animals and humans.  The ombudsman does not 
carry out all functions itself, but merely instigates, informs, promotes and 
suppresses according to the signals in its environment. 
 
Future directions 
In the context of healthy physiology, RAGE seems to be an effective modulator of 
inflammation and cell stress. The challenge appears when prolonged 
disturbances lead to chronic inflammation.  Under these circumstances, RAGE 
becomes overwhelmed by excesses of ligands and amplification loops, and 
ceases to adequately regulate signals.  Hence, specific blocking of RAGE could 
contribute positively to resolution of inflammation in diseases including diabetes, 
atherosclerosis, Alzheimer’s disease, some types of cancer, and SLE.  Due to its 
natural ability to block membrane bound RAGE, sRAGE is a clear candidate for a 
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therapeutic agent; however, no clinical trials involving sRAGE administration 
have been published to date.  Indirect methods of raising sRAGE levels, such as 
agents that promote cleavage of surface-bound RAGE by extracellular 
proteases, might be another means  to achieve the desired blocking effect. 
Antibodies and peptides capable of directly blocking the ligand binding site(s) of 
RAGE may also be of therapeutic benefit. A RAGE-blocking compound, 
presumably of this type, is currently in clinical trial in the United States for 
treatment of Alzheimer’s disease253.  Intervention in receptor-mediated pathways 
can involve compounds that activate (agonists) as  well those that block 
(antagonists).  An application for RAGE agonists, rather than antagonists, seems 
less likely to have therapeutic potential in inflammatory disease.  However, one 
could speculate that RAGE agonists might be beneficial in accelerating 
development, for instance in the lungs  of premature infants, or in cases of 
peripheral nerve damage.  
 General immunosuppresive agents, such as corticosteroids, and general 
immune stimulators, such as IFN-α, often generate significant side effects in 
patients254,255.  Design of modern therapeutics focuses on chemical and 
biological agents which can serve as “silver bullets” that target very specific 
inflammatory signaling axes, to achieve desired immune modulation without off-
target effects.  Hence, clarifying the multiplicity of roles for RAGE in ligand 
uptake, trafficking, and signaling will likely aid in this sort of cutting-edge drug 
design.
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 In terms of the nucleic acid - RAGE axis considered here, several key 
questions remain to be addressed.  Identifying the specific cell types  that mediate 
the phenotype of RAGE-dependent immune responses in the lung is a crucial 
first step.  RAGE is expressed on both pulmonary epithelium and on immune 
cells.  Expression of nucleic acid sensing TLRs is limited to a small subset of 
leukocytes, and hence, a role for RAGE in enhancing nucleic acid-TLR 
interaction is  likely to be most relevant in these cell types.  However, epithelial 
cell activation, characterized by the release of chemokines and expression of 
surface markers, plays an important role in immune cell recruitment.  Defining the 
relative roles of these cell types when RAGE comes into contact with 
extracellular DNA is  essential for dissecting how RAGE modulates immune 
responses that are ultimately dependent on activation of intracellular receptor 
proteins.  Defining the relative role of distinct cell types in response to nucleic 
acids may also shed light on how RAGE intervenes in other inflammatory 
diseases that involve vascular pathology, such as atherosclerosis and diabetes.  
 Signals that originate directly from RAGE, in addition to those from 
classical nucleic acid sensors, also require further interrogation.  MAP kinase and 
ERK phosphorylation, NF-κB activation, and cytokine release upon DNA 
stimulation of RAGE-expressing cells  were addressed but not found in my 
studies; however, activation of these factors  by RAGE upon ligand binding has 
been established clearly by others  (see Chapter I).  It is  likely that cell type, 
relative expression level of RAGE isoforms and downstream signaling 
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intermediates, and other physiological factors influence RAGE signaling in 
response to a particular ligand.  Defining the cell types responsible for RAGE-
based responses to nucleic acids in vivo (as discussed above) may aid in 
determining the conditions required to assay direct RAGE signaling in response 
to nucleic acids in cell-based assays.
 RAGE-enhanced activation of receptor axes other than TLRs are also an 
interesting avenue to pursue.  As discussed earlier in this chapter, there is reason 
to suspect that nucleic acid-containing RAGE ligands may activate 
inflammasomes that regulate maturation of IL-1 family cytokines.  IL-1 blockade 
is  a broad therapeutic strategy employed for certain inflammatory conditions256. 
Due to the subtle nature of RAGE-based inflammatory modulation, preferential 
blockade of RAGE rather than IL-1 in inflammasome-related disorders may 
provide an attractive “silver bullet” approach. 
 The manner in which RAGE directly or indirectly interacts  with the actin 
cytoskeleton is  one of the least studied and perhaps one of the most interesting 
aspects of RAGE biology.  In terms of interactions with nucleic acid sensors, 
understanding RAGE’s relationship with the cytoskeleton may shed light on the 
trafficking processes that bring intracellular sensors in contact with extracellular 
stimuli.  The manner in which intracellular nucleic acid sensors  “decide” to traffic 
between compartments such as  the ER and endosomes is still largely unknown. 
It is attractive to speculate that RAGE, as a first-line receptor for nucleic acids on 
the cell surface, might initiate cytoskeleton-based intracellular trafficking of 
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sensor proteins to functional compartments.  Understanding the specific manner 
in which RAGE integrates extracellular signals with intracellular structural 
changes may also clarify how molecular patterns induce cell motility and the 
tissue remodeling processes that lead to fibrosis and other forms of pathology.    
 In conclusion, the promiscuity and subtlety of RAGE make it both a central 
factor in receptor-mediated recognition of extracellular proinflammatory signals, 
and an integrator of multiple messages.  As this body of work clearly defines 
RAGE as a nucleic-acid binding receptor, the implications of DNA and RNA 
interacting with RAGE add a novel set of pieces to the puzzle of how this  protein 
detects homeostatic perturbations and promotes their resolution.  
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